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Summary    vi 
SUMMARY 
Heart attacks and strokes currently kill more people every year than cancer and HIV combined. These 
cardiovascular diseases are  caused by atherosclerosis  ‐  the  formation of  so‐called  “plaques”  in blood 
vessels.  Interestingly, an enzyme called “Fibroblast Activation Protein (FAP)” contributes to arthritis and 
inflammatory  liver  disease;  both  of  which  are  governed  by  similar  inflammatory  mechanisms  as 
atherosclerosis.   However the role of FAP  in atherosclerosis had never been  investigated.   The studies 
presented  in  this  thesis  find  that FAP  is  “switched‐on” by  inflammation  in potentially  life‐threatening 
atherosclerotic plaques.   We  also  found evidence  that  FAP  contributes  to plaque destabilization;  the 
main cause of heart attack and stroke.  When plaques rupture open, blood clots form, which block the 
vital flow of oxygen in a dangerous process known as “atherothrombosis.”  Our research found that FAP 
contributes to atherothrombosis in patients who suffered a heart attack.  These findings may motivate 
both the development of anti‐FAP drugs, and also diagnostic measurements of FAP for heart attack and 
stroke prevention.           
Zusammenfassung                                               vii 
ZUSAMMENFASSUNG 
Koronare Herzerkrankung und Schlaganfall töten heutzutage mehr Menschen als Krebserkrankunegn 
und HIV zusammen. Diese Herzkreislauferkrankungen werden verursacht durch Atherosklerose, welche 
der Entwicklung sogenannter „Plaques“ in den Blutgefässen entspricht. Interessant erscheint dabei, dass 
ein  Enzym  ‐  „Fibroblast Activation  Protein“  (FAP)  ‐  eine wichtige  Rolle  bei Arthritis  und  chronischen 
Lebererkrankungen  spielt, wobei  in beiden  Erkrankungen  ähnliche  Entzündungsmechanismen wie bei 
der  Arteriosklerose  nachgewiesen  wurden.  Dennoch  wurde  die  Rolle  von  „FAP“  im  Bereich  der 
Arteriosklerose  bisher  nicht  untersucht.  Die  vorliegenden  Studien  zeigen,  dass  FAP  durch  die 
Entzündung  von  potenziell  bedrohlichen  Plaques  „aktiviert“ wird. Dabei wurden Hinweise  gefunden, 
dass FAP zu Komplikationen in den Plaque führt, welche ihrerseits als Hauptquellen von Herzinfarkt und 
Schlaganfall gelten. Wenn diese Plaques aufbrechen, entstehen „Blutgerinnsel“, welche den Durchfluss 
des lebenswichtigen Sauerstoffs hemmen. Dieser gefährliche Prozess wird „Atherothrombose“ genannt. 
Unsere Ergebnisse zeigen, dass FAP zur Entwicklung von Atherothrombose bei HerzinfarktpatientInnen 
beiträgt.  Diese  Entdeckungen  konnten  die  Entwicklung  von  „Anti‐FAP‐Medikamenten“  und 
diagnostischen Messungen des FAP zur Prävention von Herzkreislauferkrankungen stimulieren. 
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Figure 1. Atherosclerosis reduces arterial blood 
flow.  Adapted from Healthwise, Inc.  
 
 
250
350
450
550
1900 1925 1950 1975 2000
A
th
er
os
cl
er
os
is
-R
el
at
ed
 D
ea
th
s 
in
 th
e 
U
SA
(D
ea
th
s/
10
0,
00
0 
pe
op
le
)
Year
Figure 2. Atherosclerosis-Related Deaths in the USA in 
the 20th Century.  Adapted from 1.  
 
 
1.1 ATHEROSCLEROSIS 
 
1.1.1  HISTORY AND SOCIOECONOMIC IMPACT OF ATHEROSCLEROSIS 
 
A Brief History of Atherosclerosis – an ancient disease 
 
Atherosclerosis is characterized as the formation of arterial 
plaques consisting largely of fat, cholesterol, and cellular wastes 
which reduce blood flow (Figure 1).  Recently, atherosclerosis 
has been linked to risk factors associated with the modern 
western lifestyle including: high-fat and high-glucose diets, lack 
of exercise, and cigarette smoking.  However, paleopathological 
investigations of ancient Egyptian mummies reveal that 
atherosclerosis was present as early as 1980 BC. 15,   Egyptians of 
the highest social status, who consumed exclusive diets rich in 
animal products and saturated fats, were often mummified.  In 
contrast, the Egyptian peasantry consumed strictly vegetarian 
diets.  Coronary plaques identified in mummies of the Egyptian 
aristocracy suggest that atherosclerosis is an ancient disease, induced by diet, and that the modern day 
atherosclerosis epidemic may simply be history repeating itself. 16      
 
“The Atherosclerosis Epidemic” 
 
In modern western civilization, the occurrence of clinical atherosclerosis-related events (including 
heart attack and stroke) increased sharply around 1920 (Figure 2).  While this sudden increase 
temporally associates with industrialization, its cause remains debated.  However, many clinicians and 
scientists concur with two leading explanations.   
The first argument suggests that environmental changes such as increased cigarette smoking and 
higher consumption of animal fats consumed in the 1920’s were central to the increase in 
atherosclerosis-related deaths.17  This hypothesis is supported, for example, by findings in one study 
which investigated the ages of death in an extended 
Dutch family with genetic hypercholesterolemia.   Half of 
these family members had a mutation in the gene for the 
low-density lipoprotein (LDL) receptor, and therefore 
experienced severe high blood cholesterol levels resulting 
in early death from coronary heart disease or stroke.  
Between 1830 and 1989, age-adjusted deaths in this 
family were drastically increased.18 This increase was too 
rapid for genetic adaptation, therefore suggesting that 
environmental changes were responsible for the sudden 
observed increase. 
The second hypothesis explaining the sudden increase 
of atherosclerosis-related death suggests enhanced 
sensitization of physicians to coronary artery disease, and 
improved diagnostic capacities afforded by the 
electrocardiogram (ECG). Moreover, the use of leukocytosis measurements and red blood cell 
Chapter 1  3 
Figure 3. Percentage of the Decrease in Deaths from Coronary Heart 
Disease Attributed to Treatments and Risk-Factor Changes.  Adapted 
from 8. 
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Figure 4. Atherosclerosis is the Leading Cause of Death in the United 
States (data taken in 2007).3 
sedimentation rates were also brought to routine clinical use for diagnosis of myocardial infarction.17  
Taken together, it is probable that both the improved diagnostic capabilities and the introduction of pro-
atherogenic factors during the industrialization contributed to the sudden increase of reported 
atherosclerosis related deaths. 
 
The Modern Decrease in Atherosclerosis Related Deaths 
 
Mortality from atherosclerosis-related has recently been cut in half since reaching its peak in 1968 
(Figure 2).  Two primary factors are responsible for this decline. First, there has been a major reduction 
in the prevalence of classical cardiovascular risk factors (i.e. smoking and high cholesterol diets) due to 
more health-conscious lifestyles.8  However it should be noted the hallmark risk factor, obesity, has 
increased strikingly in recent years, particularly in younger generations, which threaten to halt this 
favorable trend.19 
The second cause for the recent reduction in 
cardiovascular-related deaths is the drastic 
improvement in treatments against coronary 
artery disease and stroke.  Recent therapies 
including thrombolysis, coronary-artery bypass 
grafting, stents, angiotensin-converting-enzyme 
inhibitors, and statins have been instrumental 
towards preventing myocardial infarction and 
stroke (Figure 3).8  In fact, a recent comparison 
between the relative contribution of reduced 
cardiovascular risk factors, vs. improved 
therapeutics in the observed reduction of 
cardiovascular-related deaths reveals that 
nearly half to this reduction is attributed to 
improved treatment, and half to a reduction of risk factors (Figure 3).  However, it is interesting to note 
that improved treatment is now the most effective preventative measure against atherosclerosis-related 
deaths.  
 
Atherosclerosis today – where do we stand? 
 
Despite an improving trend, atherosclerosis 
remains the leading cause of death in the 
western world, killing more Americans and 
European Union members every year than 
human immunodeficiency virus (HIV) and 
cancer combined (Figure 4).3, 20  According to 
the U.S. National Center for Health Statistics, 
approximately 6 years of life could be gained, 
per person by the complete elimination of 
atherosclerotic disease.21  Therefore it 
appears indeed true that some people may 
“only be as old as their arteries.”      
In 2010, the estimated mean direct cost of care for patients diagnosed with stroke or myocardial 
infarction in the United States was $579/month for 12 months before and $1,074/month for 12 months 
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Figure 5. Six Layers of the healthy human artery. Adapted from 
Visuals Unlimited, Inc.  
Figure 6. Healthy human coronary endothelium visualized by 
scanning electron microscopy.  Endothelial cells are aligned in the 
direction of blood flow adapted from9.  
 
after diagnosis.22   Indeed, the economic burden of atherosclerosis is immense at an estimated cost of 
$156.4 billion in the United States in 2008 alone.23 
 
1.1.2  THE HEALTHY ARTERY 
An understanding of atherosclerosis requires 
knowledge of the anatomy, physiology, and cellular 
composition of the healthy human artery.   
 
Endothelium 
Healthy human arteries are most often described as a 
six-layered micro-anatomical structure (Figure 5).  The 
inner most layer of the artery is called the endothelium.  
Under normal conditions, endothelial cells form a 
monolayer (Figure 6) which acts as an interface 
between circulating blood in the lumen and the rest of 
the arterial wall.  The healthy endothelium has two 
known key functions.  First, it provides a non-
thrombogenic surface that prevents blood coagulation.  
Second, the endothelium acts as a “gate keeper” by 
selectively controlling the passage of circulating blood 
cells (i.e. monocytes and lymphocytes) and active 
molecules (i.e. nitric oxide and L-arginine) into and out 
of the arterial wall. The endothelium is tightly regulated 
by both cellular and systemic physiological mechanisms.  
However, these pathways and mechanisms often go 
awry during the formation of atherosclerosis, or so-
called “atherogeneis.”     
Tunica Intima 
The tunica intima (often referred to as simply “the intima”) includes the endothelium, which covers a 
so-called “basement membrane.”  The basement membrane is an organized extracellular matrix (ECM) 
including collagen, laminin, fibronectin, and proteoglycans.24   With aging, the intima thickens due to 
immigration of smooth muscle cells and their deposition of ECM.  Beneath the basement membrane lays 
the internal elastic lamina; a fenestrated layer comprised of condensed elastin (Figure 7).  The internal 
elastic membrane contributes to the elastic recoiling of the arterial wall following application of outward 
pressure during left ventricular systole.   
Chapter 1  5 
Figure 7. Histology of a muscular artery as visualized by aldehyde 
fuschin staining.  Adapted from quizlet.com. 
 
Figure 8.  Lipid accumulation in the intima of rabbits injected 
with bolus dose of LDL.  Adapted from5. 
 
 
Tunica Media 
 
The tunica media (often referred to simply as 
“the media”) is located beneath the internal 
elastic membrane, and is comprised of well-
organized, concentric layers of smooth muscle 
cells.  These muscle cells are surrounded by 
elastin-rich ECM.  Similar to the internal elastic 
membrane of the intima, the media also provides 
regulated arterial compliance.  Smooth muscle 
cells in healthy arteries are mostly quiescent, and 
experience low proliferation rates along with low-
levels of cellular death. Moreover, ECM content 
does not significantly change in healthy human 
arteries over time.  The external elastic membrane 
demarcates the outer boundary of the tunica intima and the beginning of the tunica externa (Figure 7).25   
 
Tunica Externa 
The tunica externa is most often referred to as the “adventitia,” and has received little attention 
compared to the intima and media as to its role in vascular physiology.  The adventitia is comprised 
mostly of disorganized collagen fibers, and a sparse distribution of adipocytes, mast cells, and 
fibroblasts.  Recently, the adventitia has been shown to harbor mesenchymal progenitor and stem 
cells.26  While it is plausible that these cell populations are involved in vascular homeostasis and 
regeneration following injury, their role in vascular physiology and atherogenesis remains largely 
conjectural.10 
 
1.1.3 THE ONSET OF ATHEROSCLEROSIS 
Low Density Lipoprotein Accumulation in the Intima 
While atherosclerosis begins within the first 
decade of life, the initial triggers of atherosclerotic 
plaque formation, and their physiological 
mechanisms of action are not yet fully understood 
understood.27 However, most scientists and 
clinicians concur with a growing body of scientific 
evidence which suggests that atherosclerosis is 
initiated by diets high in cholesterol and animal-
derived fats.  Ingested low-density lipoprotein 
(LDL) seems to play a particularly important role in 
the early onset of atherosclerosis.  The notion of 
diet induced atherosclerosis is partially supported 
by electron microscopic evidence of experimental 
ATHEROSCLEROSIS                     6 
         
Figure 9. Hypercholesterolemia-induced leukocyte-endothelium binding 
and diapedesis.  A. Scanning electron micrograph of an aortic endothelium 
from a non-human primate on a normal diet(control).  B.   Scanning 
electron micrograph of an aortic endothelium from a non-human primate 
on a high saturated fat/high-cholesterol diet (leukocyte are white).  C. 
Leukocyte diapedesis through the endothelium.  Adapted from 11. 
animals infused with LDL.  In this pioneering work, it was observed that lipid particles attach to the 
intimal ECM of rabbits and further associate into aggregates shortly after LDL injection (Figure 8). 5    
Additional studies using labeled LDL in rabbits also reveals an association between regions of LDL 
deposition and regions of plaque formation.28 The mechanism by which LDL passes though the 
endothelium to reach the intimal ECM has been addressed in many studies, which conclude that the 
endothelium is in a natural state of disruption at sites prone to atherosclerosis formation.29 Indeed, 
studies of fluid dynamics colocalize atherosclerosis-prone regions to sites of low endothelial shear stress 
and turbulent flow, whereas vascular regions exposed to laminar flow and high endothelial shear stress 
are less prone to lesion formation.30, 31  These observations can partially be explained by further in-vivo 
data suggesting accelerated EC turnover in areas with disturbed flow and low shear stress.32  
Accelerated cell proliferation plausibly enhances LDL permeability through the endothelium, by 
temporarily leaving the intima exposed to the blood stream; thereby exposing circulating LDL to the 
intima.33    
 
Oxidation of Low Density Lipoprotein 
While blood serum LDL levels associate with atherosclerotic plaque burden, native LDL itself plays a 
minimal role in atherosclerosis onset.34  Yet, LDL’s chemically modified derivate, oxidized LDL (oxLDL) is a 
potent trigger of early plaque formation.  LDL oxidation is catalyzed by its molecular binding to 
proteoglycans in the arterial intima. Moreover, in-vitro studies indicate that proteoglycan-bound LDL 
exhibits enhanced susceptibility to oxidation compared to unbound circulating LDL.35   
Active contributors to the oxidative transformation of LDL include, but are not limited to:  
• cigarette smoking (via enhanced F2-iso-prostane levels) 36,  
• bacterial infection (via lipopolysaccharide exposure) 37,  
• yeast infection (via zymosan exposure) 37, 
• exposure to chemical agents (i.e. turpentine)37,  
• excessive alcohol consumption (> two drinks/day),38    
• lipoxygenases expressed by infiltrating leukocytes39 
Moreover LDL can be transformed into pathological aggregates via sphinomyelinase40 and also undergo 
glycation due to enhanced blood-sugar concentrations associated with diabetes.41  Conversely, myriad 
antioxidants including grape-derived phenolic compounds42 and vitamin E43 are protective against LDL 
oxidation.   
 
Leukocyte Infiltration 
The second morphologically definable 
event during atherosclerosis onset is 
leukocyte recruitment into the intima.  
Under healthy conditions, circulating 
leukocytes do not firmly adhere to the 
arterial endothelium.  Even in inflamed 
tissues, leukocyte adhesion to the 
endothelium typically occurs in the post 
capillary venules, rather than in the 
arteries.44  However, hypercholesterolemia 
rapidly (<8 hr in rabbits) induces leukocyte 
adherence to the arterial endothelium, and directs diapedesis of leukocytes between endothelial cell 
Chapter 1  7 
Figure 10.  The role of monocytes in early atherosclerosis.  Adapted from 4. 
junctions and into the intima (Figure 9).45,46  Specifically, modified LDL has be shown to enhance 
leukocyte binding to the endothelium  by upregulating expression of vascular cell adhesion molecule 1 
(VCAM-1).47  VCAM-1 selectively binds monocytes and lymphocytes to the endothelium thereby 
initiating their migration into the intima towards modified LDL (Figure 10).   Moreover, oxLDL has been 
shown to induce monocyte chemotactic protein 1 (MCP-1), a potent  chemo-attractant, and the binding 
of MCP-1 to its receptor chemokine (C-C motif) receptor 2 (CCR2) contributes to monocyte and 
lymphocyte migration into the arterial intima.48   
 
Monocytes/Macrophages  
 
 Intimal monocytes quickly differentiate into macrophages, and lipid uptake by macrophages plays a 
central role in the pathophysiology of atherosclerosis.  Macrophages express so-called “scavenger 
receptors” which bind oxidized or glycated lipoprotein particles and signal their internalization to 
generate foam cells.4  Foam cells are a hallmark cell population characteristic of atherosclerotic lesions, 
which were named after their “foamy” appearance under the microscope as the result of intracellular 
lipid accumulation.  Foam cells in turn express myriad pro-inflammatory cytokines and reactive oxygen 
species which provoke local inflammation.  Foam cells may eventually become apoptotic to form the 
“necrotic core” characteristic of advanced atherosclerotic lesions (Figure 10).4       
 
T-Lymphocytes  
 
Similar to monocytes, T Lymphocytes (commonly referred to as T-Cells) also transmigrate through the 
arterial endothelium and into the intima, where they contribute to the formation of atherosclerosis 
(Figure 11).  However, unlike monocytes which are attracted primarily by MCP-1, T-Cells are recruited 
towards gradients of inducible protein 10 (IP-10), monokine induced by interferon-γ (MIG), and 
interferon-inducible T-Cell α-chemoattractant (I-TAC). Each signaling molecule is derived from the local 
inflammatory response within the atherosclerotic plaque, and bind to T-Cells via chemokine receptor 
CXCR3.2, 4   
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Figure 11.  The role of T-Lymphocytes in early atherosclerosis.  Adapted from 4. 
Intimal T-cells encounter both endogenous antigens (i.e. oxidized LDL and glycated LDL) and also 
antigens of microbial origin (i.e. lipopolysaccharides) which initiate the release of cytokines, and/or 
promote the differentiation of the T cells in the predominantly “pro-inflammatory” TH1 phenotype, or 
the “anti-inflammatory” TH2 phenotype.   Moreover, binding of T-Cell ligand CD40 to macrophage-
expressed CD154 has been shown to induce macrophage expression of tissue factor, matrix 
metalloproteinases (MMPs), and pro-inflammatory cytokines; each contributing to the pathophysiology 
of atherosclerosis (Figure 11).4 
 
Dendritic Cells 
 
Dendritic cells (DC) are the most potent antigen-presenting cells and indeed play an important role in 
atherosclerosis. In the early atherogenesis, dendritic cells differentiate in the intima from monocytes, 
where they play an active role in both the adaptive and innate immune response.  While DCs are found 
even in the subendothelial layer of apparently non-diseased arteries, it is known that comparatively 
increased amounts of subendothelial DCs are found in atherosclerosis prone regions of the vasculature.  
In atherosclerosis lesions, additional DCs invade via the inflamed endothelium and neovasculature of the 
vasa vasorum. As similar to other peripheral tissues, DCs are crucial to antigen capture, and 
presentation; a central process for T-Cell activation, and consequent release of pro-atherogenic 
cytokines.  Dendritic cells themselves have also been shown to secrete high levels of pro-inflammatory 
TNF-α and interferon gamma upon activation within atherosclerotic plaques. 49, 50  
 
Mast Cells 
 
A growing body of evidence also suggests that mast cells play an important, albeit lesser role 
compared to other leukocytes, in early atherosclerotic lesion formation.51  In-vitro data suggests that 
mast cells transmigrate into the intima towards an eotaxin gradient where they undergo degranulation 
and release the hallmark pro-inflammatory cytokine tumor necrosis factor alpha (TNFα) and MMP 
activating proteases tryptase and chymase, which promote lesion formation and plaque 
destabilization.52  
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Figure 12.  Pathogenesis of Atherosclerotic Plaques.  Image released for free public 
use via the GNU Free Documentation License. 
 
1.1.4  FORMATION OF ATHEROMATA  
Type I  – Initial Lesion 
Atherosclerotic plaques are classified into five different histological classes ranging from an early Type 
I “fatty streak” to potentially life-threatening Type VI complicated lesions.53, 54   Type I lesions have been 
observed in atherosclerosis prone regions as early as human infancy, and are characterized by the first 
microscopically and chemically detectable lipids in the intima.  Moreover, the cellular reactions including 
intimal leukocyte infiltration, foam cell formation, and early SMC-associated intimal thickening are often 
detectable.55   
 
Type II – Fatty Streak 
Type II lesions are identified by 
so-called “fatty streaks”, which are 
visible as yellow-colored streaks, in 
the intima.56  The fatty streak in 
human arterial biopsies is of 
sufficient size such that it may be 
detected by the unaided eye.   
Cellular components of the fatty 
streak include lipid laden smooth 
muscle cells and macrophages 
(foam cells).  Type II lesions also 
contain greater amounts of 
macrophages without lipid droplets 
compared to type I lesions.57  T-
lymphocytes and mast cells are 
typically found in the intima at 
much reduced numbers compared 
to macrophages.  Both mechanical 
forces on the early lesion, and 
traditional risk factors including 
blood-cholesterol levels and blood 
pressure contribute to the 
transformation of Type II lesions 
into more advanced Type III 
lesions.58   
 
Type III – Intermediate Lesion 
Type III intermediate lesions are 
also referred to as a pre-atheroma, 
and depict the morphological and 
chemical bridge between type II 
lesions and type IV atheroma.59  
While a type IV lesion is comprised 
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Figure 13. Schematic representation of  the role of progenitor cells in the 
progression of atherosclerosis.  (A) Endothelial cells covering and early lesion 
are derived from circulating endothelial progenitor cells. (B) Progenitor cell 
differentiate into Neo-SMCs above the necrotic core.   Also smooth muscle 
progenitor cells (SMC progenitors) may migrate via the vaso vasorum in the 
plaque.  Adapted from 10  
 
of a distinct lipid core and significant intimal disorganization, type III lesions show early signs of 
extracellular lipid pools.  These pools typically form among the layers of smooth muscle cells in the 
thickened intima, immediately below a layer of macrophages and macrophage foam cells.  Such lipid 
depositions replace resident intercellular matrix proteoglycans.  However, at this stage a well-defined 
lipid core is not yet developed.58    
Smooth Muscle Cell Migration 
 
The initiation of atherosclerosis primarily involves LDL accumulation, endothelium function, and 
leukocyte migration.  However the formation of atheromata involves smooth muscle cells.  At birth, the 
arterial intima does not contain smooth muscle cells. However, during atheroma formation, smooth 
muscle cells are known to accumulate within the intima.  Currently, there are two putative origins of 
intimal smooth muscle cells.  The first purported origin is the underlying media.   This theory is 
supported by evidence which indicates that smooth muscle cell chemoattractants including platelet-
derived growth factor (PDGF) are secreted by activated plaque macrophages.54, 60   
 
Progenitor-Derived Smooth Muscle Cells 
 
The second purported origin of intimal 
smooth muscle cells is that of circulating 
smooth muscle progenitor cells.  Circulating 
stem/progenitor cell populations have been 
shown to play a role in murine atherosclerosis 
formation by giving rise to neo-smooth 
muscles cells (Figure 13).  Once migrated into 
the intima, these cells are believed to 
contribute to intimal thickening and vascular 
remodeling.61  Endothelial cells which cover 
early lesions have a reduced lifespan due to 
pro-apoptotic stimuli by local inflammatory 
cytokines and low fluid sheer stress.  When 
endothelial cells die, the sub-endothelial 
intima becomes temporarily exposed to the 
blood, thereby allowing an opportunity for 
progenitor cells to invade the intima (Figure 
13).10  These progenitor cells can then 
differentiate into so-called neo-SMCs.  It has is 
also been observed that smooth muscle 
progenitor cells in the adventitia migrate to 
the intima via the vasa vasorum.  While these 
mechanistic findings are primarily supported 
by animal studies, the identification of 
progenitor cells in human atherosclerotic plaque supports the notion of their role in atherogenesis.61, 62  
While the role of the progenitor cells in human atherogenesis remains largely conjectural it is generally 
accepted that progenitor cells are beneficial in vascular healing and impair atherosclerotic plaque 
formation.63   
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Figure 14.  Intraplaque hemorrhaging  
contributes to a “step-wise” progression 
of atheroma formation.  A Type V 
human coronary plaque (A) with a 
necrotic core (NC) fibrous cap (arrow) 
shows intraplaque hemorrhaging as 
visualized by an erythrocyte membrane 
component glycophorin A  within the 
plaque (B).  The traditional model of 
steady plaque progression (C) is 
compared to a current hypothesis of 
“step-wise” atheroma formation (D) due 
to reoccurring intraplaque 
hemorrhaging.  Adapted from 1, 2   
 
1.1.5  ADVANCED ATHEROSCLEROTIC PLAQUES 
 
Type IV - Atheroma 
 
Type IV atherosclerotic plaques are the earliest form of the so-called “advanced lesions”, and show 
severe intimal disorganization caused by an extracellular lipid core.   The lipid core appears to develop as 
smaller isolated extracellular lipid pools merge to form larger pools.  Further growth of the lipid core is 
caused by continuous lipid transport from the blood.  The intimal region between the lipid core and 
endothelium typically contains lipid-laden macrophages, smooth muscle cells, and to a lesser extent, 
lymphocytes and mast cells.     Despite the classification of atheromata as advanced atherosclerotic 
plaques, fissures in the lesion surface and signs thrombosis are rarely observed.59   Also the significant 
buildup of fibrous tissue is not yet present.  However, the potential clinical significance of type IV lesions 
can be great, because the tissue region between the lipid core and blood stream is mechanically weak 
due to the lack of mature tissue formation.   Therefore, Type IV lesions are particularly susceptible to the 
formation of fissures which often result in thrombosis and cardiovascular events.53    
 
Type V – Fibroatheroma 
 
Type V fibroatheromata are distinguished from type IV atheromata by the appearance of fibrous 
tissue.  Fibrous tissue formation mimics that of reparative connective tissue, and forms around the lipid 
core.  The fibrous tissue which forms between the lipid core and the endothelium is referred to as the 
“fibrous cap”.  The thickness of the fibrous cap is a key indicator of atherosclerotic plaque stability.  It is 
frequently observed that new fibrous tissue accounts for a greater thickness of the lesion, than does the 
underlying lipid pool.  The newly formed fibrous tissue consists of substantial increases in collagen and 
smooth muscle cells and occasionally, thrombi which have been incorporated into the fibrous cap and 
are re-organized.64  Fibroatheroma are often multi-layered, containing several isolated lipid cores, 
separated by layers of fibrous tissue.  Moreover, significant calcification is often observed in type V 
lesions.  Importantly, as with type IV lesions, type V lesions may develop fissures, hematoma, and/or 
superficial thrombi (type VI lesion), and for this reason too they are clinically relevant. 53 
 
Type VI – Complicated Lesion 
 
Atherosclerotic plaque-derived morbidity and mortality are believed to be most attributed to type IV 
atheromata, and type V fibroatheromata due to lesion rupture and thrombus formation. Lesions which 
show signs of surface defects or 
thrombus formation are labeled 
type VI, or complicated lesions.  
Surface defects may vary, but can 
typically be visualized under a 
microscope.  The smallest defects 
may described as a partial loss of 
the endothelium to more severe 
deep fissures which expose the 
bloodstream to the plaque 
core.65  These surface defects 
often result in thrombosis, which 
leads to cardiovascular events.  
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The surface defects which cause thrombotic deposits are often recurrent. These thrombi, in turn, are 
known to be incorporated into the lesion, which may contribute to narrowing of the arterial lumen.  
However some thrombi enlarge to occlude the entire arterial lumen within hours or days, and are 
thereby life-threatening.53           
 
Intraplaque Hemorrhage - Role of the Vasa Vasorum  
 
The arterial microcirculation is characterized by a network of newly formed vessels called the vasa 
vasorum.  The vasa vasorum in healthy large arteries form a network of microvessels that originate 
primarily in the adventitial layer; where they play a beneficial role supplying oxygen and nutrients to the 
outer layers of the arterial wall.66  Conversely, the vasa vasorum observed within advanced 
atherosclerotic plaque is believed to be pathogenic and accelerate atherogenesis.  Indeed, vasa vasorum 
density is increased four-fold in Type VI-complicated lesions vs. type IV and V atheromata and also 
associates with the occurrence of stroke.67, 68   
Recent studies indicate the vasa vasorum provokes plaque progression when neo-vessels within the 
plaque rupture open in a process known as intraplaque hemorrhaging.  Intraplaque hemorrhaging is 
believed to contribute to plaque progression on many levels including: deposition of free cholesterol, 
macrophage infiltration, and enlargement of the necrotic core.  Moreover, erythrocyte membranes 
which are deposited into the plaque are potently atherogenic (Figure 14 A,B).1   
While it is traditionally believed that atheroma development progresses in a linear fashion with age, a 
more current hypothesis suggests rather that short bursts of atheroma are responsible for disease 
progression (Figure 14 C,D).   According to this hypothesis intraplaque hemorrhaging contributes to brief 
and rapid acceleration of disease progression, by introducing atherogenic stimuli into the plaque.    
 
1.1.6  VULNERABLE ATHEROSCLEROTIC PLAQUES AND ATHEROTHROMBOSIS 
 
Arterial Stenosis 
 
Atherosclerosis is most often present for decades of life as an unnoticed disease.  Atherosclerotic 
plaques typically remodel the artery outwards, away from the lumen, resulting in a minimal effect on 
blood-flow, and are therefore asymptomatic.69  As atherosclerotic plaques enlarge further, they often 
undergo so-called inward remodeling, defined by encroachment on the arterial lumen and a restriction 
of arterial blood flow.2   Lesions which produce an approximate 60% reduction of luminal cross-area, 
may cause insufficient flow under conditions of increased demand such as exercise.  Specifically, in the 
coronary arteries, which vascularize the heart, limited blood flow during increased demand may result in 
chest pain called angina pectoris.   
In most cases, patients never experience angina pectoris before suffering a myocardial infarction.2 
Indeed, many clinical studies indicate that myocardial infarction is often the not the result of arterial 
stenosis.  Indeed only around 15% of myocardial infarctions are caused by plaques with stenosis of 
greater than 60% luminal occlusion.   These findings suggest that many myocardial infarctions are 
caused by atherothrombotic complications arising from previously asymptomatic plaques.65, 70        
 
Atherothrombosis 
 
Most scientists and physicians agree that physical disruption of atherosclerotic plaques is the primary 
cause of acute thrombosis.  Coronary thrombi derive from two known modes of plaque disruption; 
fibrous cap rupture and superficial intimal erosion.   While plaque rupture accounts for roughly 66% of 
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Figure 15. The Role of Platelet Activation in Atherothrombosis. Most platelets briefly contact the endothelium and then 
recirculate.  However, platelets may also contact the intimal collagen and prothrombotic smooth muscle cells (SMC) at the site of 
plaque disruption, thereby promoting their activation.  Activated platelets stably adhere to the vessel wall, directing further 
platelet aggregation; a process further promoted by thrombin.  Thrombin catalyzes the crosslinking of fibrinogen into fibrin, and 
the resulting thrombus is comprised of both polymerized fibrin and aggregated platelets.    Adapted from 12. 
 
all myocardial infarctions, superficial erosion accounts for approximately 25%.65, 71  The magnitude of the 
thrombotic process triggered upon plaque disruption is regulated by elements which determine both 
plaque and blood thrombogenicity including: local shear rate, tissue factor (TF), apoptotic 
microparticles, circulating cell populations, and others.14  An understanding of the data presented in this 
thesis requires a basic knowledge of blood coagulation pathways. 
Blood is known to coagulate according to two processes:  platelet aggregation and fibrin 
polymerization.  Some scientists believe that platelet activation is the main trigger of atherothrombosis.  
Typically, platelets circulate in an inactivated state, and interact only very briefly with the arterial wall.  
However, at the site of plaque disruption, platelets are recruited, adhere, and become activated to form 
microaggregates (Figure 15).   For information regarding the molecular mechanisms of platelet 
recruitment and activation, the reader is referred to the following review articles.72, 73   
 
The contribution of fibrin to thrombus formation is governed by two opposing mechanisms; 
fibrinolysis and fibrin polymerization (Figure 16).  Advanced atherosclerotic plaques are known to 
release factors which inhibit fibrinolysis (such as plaminogen activator inhibitor-1), and other factors 
which accelerate blood coagulation (i.e. Tissue Factor).    Myriad review publications are available for 
more complete information regarding blood coagulation pathways.74 
 
Figure 16. Blood Coagulation Pathways in 
Atherothrombosis.  The healthy endothelium 
produces tissue plasminogen activator (tPA), an 
enzyme which catalyzes the conversion of 
plasminogen to plasmin, therefore promoting clot 
lysis (fibrinolysis; fibrin is converted to fibrin 
degradation products (FDP) by plasmin).  Plaminogen 
activator inhibitor-1 (PAI-1) expression is enhanced 
in atherosclerotic plaques and neutralizes (tPA) 
activity, thereby limiting fibrinolysis.  Coagulation is 
characterized by the polymerization of fibrinogen 
into fibrin.  In this process, tissue factor (TF) is known 
to be released by disrupted plaques and combine 
with factor VIIa to activate factor Xa; an enzyme that 
catalyzes the conversion of prothrombin to 
thrombin.  In turn,  thrombin catalyzes the 
conversion of fibrinogen to fibrin, thereby promoting 
thrombus formation. Adapted from 14        
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Figure 17. Fibrous Cap Rupture.  A representative 
atherosclerotic plaque with a fibrous cap (A; white 
arrows) overlying lipid-rich areas, and a plaque 
with a fibrous cap rupture (b; black arrow) are 
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Role of Inflammation in Plaque Rupture and Atherothrombosis 
 
The fibrous cap is a layer of fibrotic connective tissue, which 
separates the arterial lumen from the prothrombogenic necrotic 
core.  Rupture of the fibrous cap is a critical trigger of 
atherothrombosis that directs cardiovascular events.  A critical 
event in plaque rupture is the degradation of the fibrous cap, 
which exposes the underlying thrombogenic core to the 
bloodstream, thereby provoking thrombosis and subsequent 
vessel occlusion (Figure 17).  Coronary fibrous caps with a  
thickness of less than 65 microns have been shown to associate 
with plaque rupture and sudden cardiac death.75  While the 
mechanical strength of the fibrous cap is provided primarily by type I collagen, collagenases including 
matrix metalloproteinases and cysteine proteases have been associated with plaque instability and the 
occurrence of acute thrombotic events.76-78   
Macrophages often accumulate in the fibrous cap and shoulder regions of rupture-prone coronary 
plaque.  Indeed activated macrophages produce matrix degrading proteases known to degrade collagen 
and destabilize the plaque.   Moreover, plaque macrophages express tissue factor in response to CD154 
(a T-Cell-surface inflammatory cytokine) which initiates thrombosis (Figure 16).   Therefore, 
inflammation contributes to plaque rupture by degrading collagen in the fibrous cap, and also enhancing 
the thrombogenicity of the plaque’s interior; thereby accelerating thrombus formation upon plaque 
disruption.79 
    
Thrombosis due to Superficial Erosion 
 
While the pathophysiology of fibrous cap rupture has received much attention, atherothrombosis 
derived from superficial erosion has been less aggressively pursued.  This may perhaps in part be 
attributed to studies of the coronary vasculature which reveal that asymptomatic platelet deposition is 
commonplace in advanced lesions, and indeed most plaque disruptions do not give rise to clinically 
apparent coronary events. However, atherothrombosis derived from intimal erosion remains a serious 
clinical concern, accounting for approximately 25% of all acute myocardial infarction-related deaths.71  It 
has been hypothesized that apoptotic endothelial cells could indeed contribute to thrombosis in areas of 
superficial erosion.  Also, inflammation induced extracellular collagenases and elastinases may degrade 
the structural components of the basement membrane, which tether the endothelium.  In turn, removal 
of endothelial cells from the basement membrane exposes platelets and coagulation factors to the 
basement membrane, thereby promoting their activation.12, 71, 80 
 
 
1.1.7 CLINICAL IDENTIFICATION OF VULNERABLE ATHEROSCLEROTIC PLAQUES  
Circulating Biomarkers 
While established cardiovascular risk factors including smoking, diabetes mellitus, and hypertension 
are used in cardiovascular risk assessment, they do not fully explain patient vulnerability to 
cardiovascular events.81    Therefore, many scientists and clinicians have pursued additional biomarkers 
to add value in clinical decision making, including: C-reactive Protein (CRP), homocystiene, and soluble 
CD40 ligand. 13, 81 Moreover, it is logical that several biomarkers could be measured simultaneously in 
relationship to each other to improve risk stratification in patients.  Most of the currently investigated 
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Figure 18.  Circulating Biomarkers of Atherosclerosis.  Investigated 
biomarkers for each stage of plaque progression are shown. IL-1 = 
interleukin 1, TNF-α  = tumor necrosis factor, MCP-1 = monocyte 
chemoattractant protein-1, sICAM = soluble intercellular adhesion 
molecule-1, sVCAM = soluble vascular cell adhesion molecule,oxLDL 
= oxidized low density lipoprotein, Lp-PLA2 = lipoprotein associated 
phospholipase A2, GPx-1 = glutathione peroxidase, MPO = 
myeloperoxidase, MMPs = matrix metalloproteinases, PlGF = 
placental growth factor, PAPP-A = pregnancy-associated plasma 
protein-A, sCD40L = soluble CD40 ligand, CRP = C-reactive protein, 
sPLA2, secretory type II phospholipase A2, SAA = serum amyloid A, 
WBCC = white blood cell count.  Adapted from 13.  
 
 
circulating biomarkers are indeed linked by a 
shared involvement in pro-atherogenic 
inflammatory processes (Figure 18).  While many 
biomarkers spill over from the plaque and into the 
bloodstream at all stages of atherosclerosis, those 
which are released immediately prior to 
myocardial infarction or stroke may hold the 
highest clinical potential.  Here, only the two most 
thoroughly investigated biomarkers (C-Reactive 
Protein and IL-6) will be addressed to exemplify 
their common link to inflammation.  For further 
review of circulating atherosclerosis biomarkers, 
the reader is referred to a review article by Koenig 
et al.13    
C-Reactive Protein (CRP) is perhaps the best 
studied pro-inflammatory biomarker with over 25 
prospective studies conducted to date.  While CRP 
is generally believed  to address the acute 
inflammatory response in the body, recent 
evidence also indicates its expression by smooth 
muscle cells and macrophages in atherosclerotic 
plaques.82  An additional study also shows that 
high CRP levels strongly correlate with vulnerable 
atherosclerotic plaque burden.83    
Interleukin-6 (IL-6) is a cytokine expressed in activated monocytes/macrophages and endothelial cells.  
IL-6 expression is typically localized to the shoulder region of unstable human plaques, where it 
contributes to enhanced free radical oxygen production and endothelial dysfunction.84, 85 IL-6 amplifies 
plaque inflammation, and is also a potent pro-coagulant cytokine involved in atherothrombosis.  Indeed, 
several studies have demonstrated a predictive value of circulating IL-6 levels for future cardiovascular 
events.  Perhaps the most relevant data are derived from the Fragmin and Fast Revascularization During 
Instability in Coronary Artery Disease II (FRISC II) studies, which demonstrate that patients with high IL-6 
level might benefit the most from an early invasive strategy, such as a coronary bypass or stenting.86 
Indeed, multiple biomarkers have been shown to predict plaque destabilization and rupture and 
subsequent clinical complications.  However, these cytokines measure the substantial relative risk of 
cardiovascular events on the order of 2-3 fold, and therefore may not yet be sufficient in clinical 
decision-making with regards to early interventions.13  This is exemplified by exhaustive clinical CRP 
studies which, taken together, have yet to define CRPs incremental value in clinical decision making 
towards cardiovascular events.  Therefore, additional biomarkers which predict the clinical 
complications of atherosclerosis are still needed.  If discovered, these biomarkers must demonstrate 
specificity, sensitivity, predictive value, practical implementation, and cost-effectiveness to ultimately be 
of significant clinical use.87        
 
Molecular Imaging 
 
60% of myocardial infarctions are caused by vulnerable plaques which go undetected by current 
clinical imaging methods (i.e. magnetic resonance imaging and intravascular ultrasound).  While 
currently employed imaging methods provide anatomical and morphological information, they cannot 
detect the biological signals which predict plaque rupture.88  Specifically, inflammatory cytokines, 
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Figure 20. Targets for molecular imaging of atherosclerotic plaques at different stages of disease progression. Schematic arterial cross 
section demonstrating different phase of atherosclerotic lesion progress and the examples of appropriate molecular targets at each stage of 
plaque progression. Adapted from 6.   
 
Figure 19. Molecular imaging of 
vulnerable atherosclerotic plaques. The 
vulnerable plaque target protein (T) is 
bound by an antibody (A). The antibody 
may be linked to a carrier particle (C) 
and a payload of signaling molecules (S). 
The emitted signals are recorded by a 
signal detector.  
 
proteolytic enzymes, and oxidative species which provoke 
atherothrombosis remain difficult to identify in vivo.  The rationale 
behind molecular imaging derives from the recognition that molecular 
and cellular processes govern vulnerable plaque disruption.  Once 
brought into the clinic, molecular imaging could have many capabilities 
including more precise visualization of rupture-prone atherosclerotic 
lesions, and provide imaging endpoints for clinical trials of anti-
atherosclerosis therapies.  Moreover the combination of molecular 
imaging with circulating biomarker analyses may someday assist in 
clinical decision making.89   
The fundamental molecular imaging approach consists of four parts; 
(i) a disease-specific target, (ii) a target binding agent, (iii) signalling 
molecules, and (iv) a signal detector (Figure 19).89  In a more 
sophisticated approach some groups have employed enzyme-specific 
probes, that when cleaved by the enzyme of interest, emit a signal for 
detection.90 Other groups have targeted specific transports with labelled 
substances which are taken up into the tissue, most notably fluorodeoxyglucose (18F), commonly 
abbreviated 18F-FDG.91   
Molecular imaging, unlike anatomic imaging, focuses on plaque biology and may therefore identify 
rupture-prone atherosclerotic plaques. Once rupture-prone plaques are identified, decisive measures 
can be employed, systemically or locally, to prevent myocardial infarction or stroke.  For example a 
decision could be made to perform coronary artery bypass or to place a coronary stent.  Conversely, a 
decision not to perform an intervention may avoid unnecessary complications and re-intervention.  
Therefore, improved molecular imaging strategies would certainly support these decisions.   Taken 
together, molecular imaging should assess the lesion-specific risk, which could then be combined with 
traditional risk factors to personalize a therapeutic strategy.92 
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Selecting suitable molecular targets is central to molecular imaging strategies.  While some molecular 
targets may be suitable for quantifying end-points of therapeutic interventions, different targets are 
perhaps more ideally suited for identifying potentially life threatening rupture-prone atherosclerotic 
lesions (Figure 20).   For example, molecular targets of inflammation, arterial remodeling, and tissue 
metabolism are perhaps best suited for determining the efficacy of anti-atherosclerotic medications.  
However, to identify rupture-prone atheromata, molecular targets must be tightly associated with 
features of vulnerable plaque rupture.  These factors include fibrous cap thickness, superficial intimal 
erosion, and sub-clinical thrombus formation.           
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1.2 FIBROBLAST ACTIVATION PROTEIN 
 
1.2.1 CLASSIFICATION OF FIBROBLAST ACTIVATION PROTEIN  
 
FAP is a Serine Integral Membrane Protease 
 
FAP is a serine protease shown to play a role in tissue remodeling during tumourogenesis, rheumatoid 
arthritis, and chronic inflammatory liver disease.  As these diseases have similar inflammatory-mediated 
pathophysiology as atherogenesis, we hypothesized that FAP is also involved in the development of 
atherosclerotic lesions.  FAP has been studied in different directions and under varying names including:  
Seprase, Fibroblast Activation Protein α, Serine peptidase, Antiplasmin Cleaving Enzyme, and Serine 
integral membrane protein.  FAP belongs to the small family of serine integral membrane peptidases, 
called SIMPs.3  SIMPs cleave proline-containing peptides and macromolecules and are active on the cell 
surface.  Proline peptidases such as prolyl endopeptidase, dipeptidyl peptidase 8, and dipeptidyl 
peptidase IV-β have also been show to modify bioactive peptides and change their cellular functions, 
and play a critical role in tumourogenesis.4, 5  FAP has similar behavior, and also plays an instrumental 
role in tumor formation and cellular function.   
 
Similarity of FAP to Dipeptidyl Peptidase IV (CD26) 
 
The most studied SIMP is dipeptidyl peptidase IV (DPPIV or CD26), which shows striking similarities to 
FAP.  Several studies demonstrate the importance of DPPIV in regulating tumor stromal cell behavior 
and function, and FAP shows up to 52% homology to DPPIV.6  Both FAP and DDPIV are also members of 
the S9b peptidase family, which is play an indirect role in anti-hyperglycaemia via degradation of the 
incretins, a group of gastrointestinal hormones that cause an increase in the amount of insulin released 
from pancreatic beta cells.2 While all SIMPs cleave prolyl peptide (Pro-Xaa), FAP’s  predominant 
distinguishing feature is its potent gelatinase activity.7, 8 Indeed, this a is key feature which differentiates 
the behavior of FAP from DPPIV.7  While the exact physiological roles of FAP are only beginning to be 
understood, insight can be obtained from the vast amount of research already performed on DPPIV. 
 
1.2.2 MOLECULAR STRUCTURE AND GENETIC CONSERVATION 
 
Molecular Structure of FAP 
 
Native expressed FAP is a 170kDa homodimer, and is often found as a type II integral membrane 
protein with a very large C-terminal extracellular domain (Figure 21).  The native monomer form of FAP 
is 97 kDa and is N-glycosylated.2  Transmembrane FAP can shed from the cell surface and, is indeed 
detectable in human blood.  The circulating form of FAP has been investigated under the name 
Antiplasmin Cleaving Enzyme (APCE), and has an approximate molecular weight of 175kDa, as it retains 
the same homodimer structure as the transmembrane variant.9  APCE also retains the same catalytic 
activity as trans-membrane FAP, whereas the FAP monomer exhibits no gelatinolytic activity.  The FAP 
monomer contains three segments which are highly conserved in serine proteases and has five potential 
N-glycosylation sites.  The cytoplamic tail of FAP on the N-terminus is only six amino acids long, and its 
biological role is not yet understood.4  The structure of the FAP homodimer has recently been resolved 
(Figure 21), which provides valuable information regarding the enzyme’s substrate specificity.2   
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Figure 21. The Extracellular Domain of Fibroblast Activation Protein. The extracellular domain has an eight bladed β-propeller domain (blue) 
and an α/β hydrolase domain (green) that contains the catalytic triad. Catalytic residues are shown, purple (Serine 624), cyan (Aspartic Acid 702), 
yellow (Histidine 734). Taken from 2. 
 
Each FAP monomer contains two distinct domains: the β-propeller domain and the α/β-hydrolase 
domain; which contains FAP’s catalytic site.  The catalytic site is located directly at the interface of the β-
propeller and the α/β-hydrolase domain. The β-propeller domain is located on top of the catalytic triad 
and appears to reduce protein access to the catalytic site. This notion is supports findings from previous 
studies of a related serine protease called prolyl oligopeptidase, which has a similar β-propeller domain 
that regulates proteolysis by excluding large proteins from the catalytic site.10  The active site is 
theoretically accessible via the cavity formed between the β-propeller (about 24 Angstroms in diameter) 
or  through the hydrolase domain (about 14 Angstroms in diameter).  This notion is supported by further 
studies using recombinant FAP which indicate that proteolytic truncation of the β-propeller domain  
reduces steric hindrance for substrates, and results in a 7-fold increase in FAPs gelatinase activity.11 
However the dipeptidyl peptidase activity of truncated FAP remained identical to the native FAP.    
 
Genetic Conservation of FAP Across Species 
 
The FAP gene is relatively well conserved in different species including Homo sapiens, Mus musculus 
(89%), and Xenopus laevis (50%). Interestingly, the catalytic domain is much better conserved between 
species than is the β-propeller domain.2  Studies of murine FAP identifies three different splice variants 
which have been detected in native tissues.  Similarly, a single splice variant of FAP, called seprase-s, has 
also been identified in a human melanoma cell line and encodes a truncated 27kDa isoform.  The 
Seprase-s isoform precisely overlaps 239 amino acids of native FAP’s catalytic domain.12   However the 
physiological role of seprase-s has not yet been investigated.  
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Figure 22. The Role of FAP and α3β1. 
α3β1 participates in the formation of 
functional invadopodia by docking 
Seprase.  Taken from.1  
 
FAP
1.2.3 INDUCTION AND CATALYTIC ACTIVITY 
 
Biochemical Properties of FAP 
 
FAP undergoes significant post translational modifications such as N-glycosylation.  Without 
glycosylation, FAP lacks all forms of detectable enzymatic activity.13  Further reports show that the 
gelatinase activity of FAP is inhibited using standard serine protease inhibitors. 2   FAP exhibits total loss 
of its enzymatic activity upon dissociation of the dimer into its 97kDa subunits, confirming that FAP 
activity depends upon the association of its subunits to form an active dimer.3, 14  The proteolytic 
optimum of FAP is at a neutral pH, and becomes inactive at under acidic conditions due to dissociation 
of the monodimer.15 
 
Catalytic Activity of FAP 
 
FAP has two known catalytic targets; gelatin and proline bearing peptides.2  Few proteases are able to 
cleave proline-linked peptide bonds.  Proline residues appear near the amino terminus of many 
biologically active peptides where they appear to protect the peptides against degradation.16  
Understanding the signaling effect of FAP-derived peptide fragments has not yet been investigated, but 
may identify additional physiological roles of FAP.  
Zymography-based specificity studies reveal that FAP degrades gelatin and collagen type I and type IV 
collagens but not laminin, fibronectin, or fibrin.3, 7  However, conflicting studies demonstrate that FAP 
does not cleave native collagen type I or III into smaller peptides.  The same study concludes that FAP 
works in parallel with other proteinases to cleave partially degraded or denatured Collagen I and III as 
ECM is excavated from remodeling tissue.17 
 
The Role of FAP in Cell Migration 
 
FAP associates with α3β1 integrin, DPPIV, MMP-2, membrane-type 1 
MMP, and urokinase-type plasminogen activator receptor at the 
invadopodia of malignant human tumor cells.  Therefore, FAP likely plays an 
interactive role with these proteinases, their receptors, and their 
associated signaling pathways.2  Specifically, FAP has been hypothesized to 
work in concert with α3β1 integrin and participate in the formation of 
functional invadopodia by tethering FAP to the ECM substrate (Figure 22).1 
FAP and DPPIV also have been shown to form a complex at the invadopodia 
of fibroblasts on collagenous fibers.  This DPPIV–FAP complex, which 
exhibits both prolyl peptidase activity and gelatinase activity, is necessary 
for fibroblast migration on a collagen substrate in vitro.18, 19  
 
Induction of FAP Expression 
 
Fibroblast activation protein is expressed in migrating fibroblasts and tissues undergoing matrix 
remodeling during wound healing.  Numerous studies show FAP expression primarily in “remodeling 
tissues,” but not in quiescent tissues, which supports the notion of regulated FAP induction.7, 8, 20, 21  
Colocalization of FAP in inflamed tissues further suggests its induction by inflammatory cytokines.  
However, it was not until recently that induction of FAP expression had been addressed.  In cancer cells, 
FAP could be induced by stimulation with tumor growth factor-β (TGF-β). 22 These finding are further 
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supported by additional investigations into the FAP promoter.  This study found that early growth 
response 1 protein (EGR1) binds to the FAP promoter, and thereby regulates its transcription. 23  
Interestingly, hallmark pro-inflammatory cytokine TNFα has been show to induce ERG1 expression in 
smooth muscle cells of experimental atherosclerotic lesions, suggesting a possible mechanism of FAP 
induction.24    
 
FAP in Tissue Remodeling 
 
Notions that FAP is involved in wound healing are supported by its expression in many tissues 
undergoing active remodeling.  Perhaps even more definitive is another study involving the Xenopus 
laevis FAP homologue, which associates the enzyme’s increased expression during hormone-induced tail 
resorption; a highly active tissue remodeling process.25   Further support of this theory can be found in 
studies of mouse embryo development, where FAP is expressed in remodeling tissues.26 To access FAP 
expression during embryonic development, mice deficient in FAP but expressing β-galactosidase under 
the control of the FAP promoter were developed. β-galactosidase strongly correlated with regions of 
active tissue remodeling during embryogenesis. However, it is important to note that FAP-deficient mice 
have no obvious developmental defects, which suggests that FAP may not play a critical role in 
embryonic tissue remodeling processes.  
 
1.2.4 THE ROLE OF FAP IN CANCER AND INFLAMMATORY DISEASES  
 
Cancer 
 
Numerous studies show that FAP is expressed during wound healing and in reactive stroma of 
epithelial cancers and in multiple sarcomas.27  However, malignant epithelial, neural and haematopoietic 
cells are generally FAP-negative, although it has been detected in astroglial tumours.28  Additional 
studies describe FAP expression in the reactive mesenchyme of epithelial tumors (carcinomas).  Further, 
FAP has been discovered in colon adenocarcinoma, lung adenocarcinoma, metastatic colon 
adenocarcinoma, ductal carcinoma in breast cancer, epithelial ovarian carcinoma, and cervical 
carcinoma.2  In-vivo studies of epithelial-derived solid tumors in mice indicate a causal role of FAP in 
stromal cell mediated pathways including tumor cell proliferation and neovascularization.29 Further 
studies show that immunization against the FAP inhibits tumor growth and increases survival in a 
murine model.30 
 
Liver Disease 
Stellate cells at the tissue remodeling interface of cirrhosis in humans have also been shown to 
express FAP.8 Indeed hepatic stellate cells are largely responsible for hepatic tissue remodeling. From 
this work, it was concluded that FAP contributes hepatic stellate cell-induced ECM changes observed 
during chronic inflammatory liver disease. FAP expression was also detected in the similar 
pathophysiology of chronic hepatitis C virus  infection, where it contributes significantly with the degree 
of hepatic fibrosis.31    
Arthritis 
 
FAP expression has been observed in osteoarthritis.   This pioneering work identified the 
expression of FAP on chondrocyte membranes under conditions that promote cartilage 
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Figure 23. Impact of APCE (soluble FAP) on the fibrinolytic sytem.   APCE impairs blood 
coagulation by activating α2-antiplasmin, which in turn inhibits plasmin-mediated cleavage of 
fibrin. Adapted from 2 
 
resorption, and also elevated expression in cartilage from osteoarthritis patients.  FAP has also 
been detected in the similar pathophysilogy of rheumatoid arthritis, where it was reported that 
FAP is expressed in the lining layer of rheumatoid synovium.  This study also reports a strong 
association of inflammatory synovitis  with FAP expression.32 While it is generally believed that 
FAP contributes the pathological breakdown of joint tissues in arthritic disease, conflicting 
pharmacological-inhibition studies in-vivo reveal that FAP actually protects articular cartilage 
against invasion by synovial fibroblasts.33  Future in-vivo analyses using FAP knockout mice may 
clarify its in-vivo causal role in arthritic disease.34 
 
1.2.5 THE ROLE OF FAP IN BLOOD COAGULATION  
 
Lee et al. discovered that 
Antiplasmin Cleaving Enzyme 
(APCE) is actually a soluble form 
of FAP.  APCE was shown to  
indirectly influence the cross-
linking of fibrin via α2-
Antiplasmin (AP).35 AP is a plasma 
glycoprotein of the Serpin (serine 
protease inhibitor) superfamily 
and is the primary physiological 
inhibitor of plasmin, a key 
enzyme in fibrin degradation.  
The fibrinolytic system leads to 
the generation of plasmin from 
plasminogen through the action 
of Tissue or Urokinase 
Plasminogen Activator (t-PA or 
uPA). FAP processes α2-
antiplasmin (α2AP) from the less 
active “PRO” form (α2APPRO) into the more potent “ACT” form (α2APACT).  The PRO-form has 
remarkably less capacity of cross-linking fibrin compared to the ACT form.  α2APACT binds to fibrin 
during clot formation, effectively inhibiting plasmin and rendering the fibrin resistant to proteolysis 
(Figure 23).9, 35 However, despite this behavior, the role or FAP in atherothrombosis is not understood. 
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1.3 AIM OF THE THESIS 
 
Fibroblast activation protein (FAP) contributes to the pathophysiology of tumor formation, arthritis, 
and liver disease. Atherosclerosis follows similar pathophysiology to these diseases; however the role of 
FAP in atherosclerosis has never been investigated.  Given the unmet need for improved diagnostic and 
therapeutic targets against atherosclerosis, the aim of this thesis is to (a) characterize FAP expression in 
atherosclerosis and examine its association with plaque instability, (b) to determine the induction and 
catalytic mechanisms of FAP as it relates to plaque complication, and (c) to evaluate the role of FAP in 
atherothrombosis. 
 
1.4 OUTLINE OF THE THESIS 
 
The experimental portion of this thesis begins with the description of an image analysis algorithm 
developed to quantify FAP expression in human carotid fibrous caps.  The presented image analysis 
algorithm quantifies the association of smooth muscle cell-specific FAP expression with carotid fibrous 
cap thickness (Chapter 2).  The next section investigates the role of FAP in human atherosclerosis. 
Experimental evidence is shown, which indicates that vascular smooth muscle cells express FAP in 
response to macrophage-derived TNFα.  The same section goes on to show that FAP associates with 
thin-cap human coronary fibroatheromata, and contributes to type I collagen breakdown in fibrous caps 
(Chapter 3).   The role of FAP in atherogenesis, and data indicating FAP-mediated acceleration of blood 
coagulation are shown (Chapter 4).  The final section provides a discussion directed at the future 
diagnostic and therapeutic potential of FAP in cardiovascular disease (Chapter 5).   
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2.1 ABSTRACT 
Background – Proteins expressed in “rupture-prone” thin-cap vs. “stable” thick-cap fibroatheromata 
of carotid plaques may be visualized by diagnostic imaging to identify patients at risk of stroke. 
Fibroblast Activation Protein (FAP), a Type I collagenase, is increased in thin vs. thick coronary fibrous 
caps. However, its role in carotid plaques, and a quantitative method linking fibrous cap thickness to 
cell-specific protein expression remains unavailable. 
Methods and Results – We describe a novel image analysis algorithm that associates protein 
expression to human carotid fibrous cap thickness.  Image analysis reveals that FAP is increased in thin 
(≤65µm) vs. thick (>65 µm) carotid fibrous caps (n=5 patients; p=0.035) and colocalizes with vascular 
smooth muscle cells, but not endothelial cells or macrophages. Finally, the presented algorithm reveals 
increased smooth muscle cell-specific FAP expression in thin vs. thick fibrous caps (n=5, p=0.026). 
Conclusions – The presented novel image analysis algorithm identifies enhanced smooth muscle cell-
specific FAP expression in thin carotid fibrous caps. This method may be applied to identify future 
molecular targets of thin-cap fibroatheromata, and also to investigate cell-specific protein regulation 
associated with fibrous cap thinning. 
 
2.2 INTRODUCTION 
 
Carotid plaque rupture is more prevalent in patients with a history of ischemic neurological events.1 
Moreover, studies of advanced carotid plaques indicate that fibrous cap thinning associates with lesion 
rupture.2  Therefore, identification of high-risk lesions is of utmost importance in neurology and 
cardiovascular medicine.  
Whereas currently applied imaging modalities identify the overall morphology of carotid plaques, 
molecular imaging of targets specific for unstable fibrous caps may specifically identify rupture-prone 
lesions.3 Thus, the identification of targets that are enhanced in “rupture-prone” thin vs. “stable” thick 
carotid fibrous caps may identify patients at increased risk for stroke. However identification of these 
targets has proven difficult, in part because no method currently exists to associate protein levels of 
imaging targets to fibrous cap thickness. 
Here we present a novel image analysis algorithm to quantify cell-specific protein expression in thick 
vs. thin human carotid fibrous caps ex vivo. Fibroblast Activation Protein (FAP) is a constitutively active 
serine protease that degrades collagen type I, a primary load-bearing component in fibrous caps, and 
thereby likely contributes to plaque destabilization.4 The presented image analysis algorithm is applied 
to quantify smooth muscle cell-specific FAP expression, and examine its association with fibrous cap 
thickness. 
 
2.3 METHODS 
 
2.3.1 CHARACTERIZATION OF CAROTID PLAQUES  
 
Patients with severe carotid plaque burden, as diagnosed by carotid doppler, underwent carotid 
endarterectomy and had the following characteristics: n = 5, age (y): 74 ±14.1 , BMI: 28.7 ± 5.5, diabetes 
mellitus: 3/5; pre-operative  CRP (mg/L):73.5±143.9. Approval from the local Ethics Committee was 
obtained for collections of all patient specimens. Carotid plaques were cryosectioned, and stained with 
Masson against collagen for characterization of fibrous cap thickness. Fibrous caps were identified as the 
collagen-rich tissue separating the lumen and the necrotic core. Fibrous caps with a minimum thickness 
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of less than 65µm were classified as thin-cap, whereas those 65µm or greater in thickness were 
classified as thick-cap fibroatheromata.5 
 
2.3.2  IMMUNOFLUORESCENCE 
 
Carotid plaque sections were fixed in ice-cold acetone for 5 min and stained for FAP using mouse 
monoclonal F19 IgG antibody and a Cy5 goat anti-mouse secondary antibody (115-175-008; Jackson 
ImmunoResearch).6  Actin was stain using a rabbit anti-human/mouse antibody (Sigma; A2066) and 
labeled with a Cy2 secondary antibody (111-225-047; Jackson ImmunoResearch).  FAP colocalization 
with macrophages, endothelial cells, and smooth muscle cells was determined using a rabbit antibodies 
directed against CD68 (SC-9139; Santa Cruz, Santa Cruz, CA), von Willebrand factor (vWF; F3520; Sigma-
Aldrich, Carlsbad, CA),  and alpha-smooth muscle actin (αSMA; Ab5694; Abcam). Subsequent fluorescent 
labeling was performed using a Cy2-labeled anti-rabbit IgG (111-225-047; Jackson ImmunoResearch) in 
three adjacent sections of each biopsy specimen.  DAPI (D9542; Sigma-Aldrich) was used for fluorescent 
counterstaining of nuclei.  Isotype control antibodies were used to address antigen-binding specificity.  
Stained samples were cover-slipped with Tris-buffered glycerol (a 3:7 mixture of 0.1 M Tris-HCl at pH 9.5 
and glycerol supplemented with 50 mg/mL n-propyl-gallate). 
 
2.3.3 IMMUNOHISTOCHEMISTRY 
 
Cryosections of carotid plaques were fixed in ice-cold acetone for 5 min and stained using a mouse 
monoclonal against FAP (clone F19, Provided by ATCC, Molsheim Cedex, France) and the appropriate 
mouse isotype control (401401; BioLegend, San Diego, CA).7, 8  Primary antibodies were detected with 
biotin-labeled goat anti-mouse (115-066-003; Jackson ImmunoResearch, West Grove, PA) and biotin-
labeled goat anti-rabbit (111-066-003; Jackson ImmunoResearch) and stained using an ABC staining kit 
(Vector Labs, Burlingame, CA) and counterstained with Mayer’s haematoxylin to visualize cell nuclei.   
 
2.3.4 IMAGE ACQUISITION 
 
For low power imaging at spatial resolutions above 1 µm/pixel, a fluorescent microscope (DM60000B; 
Leica, Wetzlar, Germany) equipped with a fluorescent camera (DFC350 FX; Leica) was used. 
Colocalization analyses, and quantification of FAP expression in smooth muscle cells were performed at 
higher magnifications using a multichannel confocal microscope (TCS SP2, Leica) on a single optical 
plane.  
To address variability due to focusing inconsistencies during image acquisition, a murine aortic arch 
was harvested, sectioned at 10µm thickness, and stained for actin with a fluorescently Cy5 labeled 
secondary antibody.  The specimen was brought into manual focus and an image was taken as the 
baseline focus level and analyzed for average pixel intensity.  Auto-focusing was then performed on the 
same specimen to identify changes in the resulting average pixel intensity.  The specimen was moved 
±4, ±8, and ±16µm away from the focused plane and an image was captured before and after auto-
focusing to determine the range at which auto-focusing provides consistency (Figure 25).        
 
2.3.5 IMAGE ANALYSIS 
 
For quantification of FAP and actin, three single-channel fluorescent images were taken for each 
specimen at constant camera settings at an auto-focused plane, in tagged image file format (TIFF) at a 
binary pixel intensity between 0-255; a sample image (with target-specific primary antibodies), a 
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Figure 25. Software auto-focus generates reproducible pixel 
intensity readouts.  Top; Graph reveals the values (red) derived from 
images of fluorescent actin-stained murine aortae captured within 
8µm of the focused position (0µm). Auto-focus generates 
reproducible readouts (blue).  Bottom; Representative images at 
specified distances (-16µm to 16µm) away from the plane of focus 
before (red) and after auto-focusing (blue; bar = 100µm).   
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background image (taken 200µm below the specimen), and an isotype control image (an adjacent 
section stained with non-specific isotype control antibodies; Figure 1A).  In each patient, three sets of 
three images (sample, background, and isotype control) were taken and the signals analyzed (nine 
images in total).  The image analysis was performed in custom developed code in Matlab (R2007b, 
Mathworks, Novi, MI).  The complete software code for the algorithm is provided in the appendix 
section of this thesis (Chapter 6).   To minimize variability due to focusing inconsistencies, all images 
were auto-focused by the image capture software; a method validated to provide consistent image 
readouts (Figure 25).  
To objectively remove the background signal 
from the image, a threshold is calculated as the 
pixel intensity below which 95% of the pixels exist 
in both the background and isotype control 
images.9, 10  Pixels below both thresholds are 
removed from the sample image and excluded. 10    
After sub-threshold subtraction, the mean pixel 
intensity is calculated for the entire image as the 
sum of all super-threshold pixel intensities divided 
by the total number of super-threshold pixels.  To 
calculate a normalized value of FAP expression 
relative to cell quantity, the mean signal of the FAP 
fluorescent channel was divided by the mean signal 
of actin channel.  Three sections with matching 
control images were averaged for each fibrous cap. 
To calculate colocalization coefficients, super-
threshold pixels positive for FAP that were also 
were positive for cell-specific markers (alpha 
smooth muscle actin, CD68, and von Wildbrand 
Factor) were calculated.  The percentage of FAP 
positive pixels also positive for a cell-specific 
marker were reported as the colocalization 
coefficient.  A qualitative impression of 
colocalization was generated by two-dimensional 
scattergram, which plot pixels on the x-axis 
according to their expression of FAP and on the y-axis according to their expression of cell-specific 
markers.11  The amount of pixels in each position is quantified by the color of the pixels in the 
scattergram.   
To quantify FAP expression in smooth muscle cells, images were taken of carotid specimens stained 
for FAP with αSMA, FAP with αSMA-isotype control, and FAP-isotype contol with αSMA-isotype control.  
The background threshold for αSMA is determined as the pixel intensity below which 95% of the pixels 
exist in both the background and isotype control confocal images.  Pixels above the αSMA threshold 
were quantified for FAP expression in both the FAP with αSMA and FAP with αSMA-isotype control 
images.  From these images, the mean pixel intensities were calculated for FAP and the FAP-isotype 
control.  The difference between the FAP signal and the FAP-isotype signal in αSMA-positive pixels is 
calculated as the difference in mean fluorescent intensity (ΔMFI; Figure 2E). 
For validation of linearity between actin concentration and the calculated signal, HEK293 cells were 
cytospun onto glass slides at a density of 1, 10, 100, and 1000 cells per cm2 and stained for actin-specific 
antibodies, and relevant isotype control antibodies.  Purchased recombinant human FAP (Origene, 
Rockville, MD) was also plated at a density of 1, 10, 100, and 1000 ng/cm2 onto a glass slide and allowed 
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Figure 26.  Calculated signal is linear to FAP and actin protein concentration. A. The average pixel intensity of Fibroblast Activation 
Protein is linear to the protein concentration (n=4, R2=0.9996, p=0.0004; bar=20µm) and the average pixel of actin (B) is linear to the 
concentration of HEK293 cells (n=4, R2=0.9852, p=0.0148; bar=20µm).  
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to dry overnight before staining for FAP and relevant isotype control antibodies.  Background images 
were taken at 200µm below the sample plane.  The emitted signals were correlated to the 
concentration of plated FAP and cells (actin). 
 
2.3.5 STATISTICAL ANALYSES 
 
Associations for the linearity validations were calculated by Pearson’s correlation coefficient. Paired 
Student’s T-test was used for comparisons of immunofluorescent images in thick vs. thin fibrous caps. 
All statistical analyses were performed using MatLab (Version, R2007b, Mathworks, Novi, MI). Data are 
presented as mean±SD. Significance was accepted at the level of p<0.05. 
 
2.4 RESULTS 
 
2.4.1 IMAGE ANALYSIS ALGORITHM QUANTIFIES FAP AND ACTIN WITHIN A LINEAR RANGE   
 
Signals calculated from the image analysis algorithm are linear with the pre-defined protein concentrations of 
FAP and actin (Figure 26). 
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Figure 27. Image analysis algorithm quantifies fibroblast activation protein expression in carotid fibrous caps.  
A. Representative stainings of a fibrous cap (by Masson) and FAP in an adjacent section (bar low magnification = 
200µm, bar high magnification = 50µm).  B. The “sample image” is taken of a carotid plaque specimen stained 
with a target-specific antibody (a) and a “background image” (b; taken at an optical plane 200µm below the 
carotid specimen), and an “isotype image” (c; adjacent section of the carotid plaque stained with an isotype 
control antibody) is subtracted. C. Representative FAP stainings of the fibrous cap (top; bar = 20µm) are shown 
in A. (dashed black box) with corresponding histogram readouts showing the frequency of pixel intensities 
(bottom).  Super-threshold pixels (green), sub-threshold pixels (red), and pixels equal to the threshold (black) 
are shown.  
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2.4.2 BACKGROUND CORRECTION PROVIDES OBJECTIVE QUANTIFICATION OF FAP IN 
FIBROUS CAPS 
 
FAP expression in carotid fibrous caps (Figure 27A) is quantified by correction of background and isotype 
control signals from a sample image (Figure 27B) followed by calculating the mean pixel intensity of the resulting 
FAP-specific signal (Figure 27C).  
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Figure 29. FAP expression colocalizes with smooth muscle cells, but not 
with macrophages or endothelial cells in carotid fibrous caps. A, Overlays of 
confocal images of FAP (red) and DAPI (blue) with cell-specific stainings of 
αSMA, CD68, and vWF (green) in representative sections illustrate FAP 
colocalization (arrows) with smooth muscle cells (bar=20 µm).   B, The graph 
quantifies an increased colocalization of FAP with smooth muscle cells 
(αSMA), compared with endothelial cells (vWF), and macrophages (CD68) in 
carotid fibrous caps (n=5).  
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2.4.3 FAP COLOCALIZES WITH SMOOTH MUSCLE CELLS IN CAROTID FIBROUS CAPS 
 
Confocal image analyses reveals FAP expression by smooth muscle cells, but not by macrophages or endothelial 
cells in human carotid fibrous caps using scattergram and colocalization coefficient calculations (Figure 29).  
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2.4.4 SMOOTH MUSCLE CELLS EXPRESS INCREASED FAP IN THIN- VS THICK-CAP HUMAN 
CAROTID FIBROATHEROMATA 
 
To determine carotid fibrous cap thickness, we labeled collagen in carotid fibroatheromata by Masson Trichrome 
staining.  Immunohistological analysis reveals qualitatively enhanced FAP expression in thin vs. thick fibrous caps 
within the same plaque specimens (Figure 2A). Finally, FAP expression is enhanced in smooth muscle cells of thin 
vs. thick fibrous caps (Figure 2B-C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 30.  Fibroblast activation protein expression is enhanced in smooth muscle cells of thin vs. thick 
carotid fibrous caps.  A. top; Representative histology of a carotid fibroatheroma (as stained by Masson for 
collagen) reveals enhanced FAP expression in thick (>65µm) vs. thin (≤65µm)  fibrous caps (bar low 
magnification = 200µm, bar high magnification = 20µm). B. top;  Immunofluorescent stainings of FAP (red), 
αSMA (green), and cell nuclei (DAPI, blue) are shown for thick vs. thin cap regions.  B. Middle; scattergrams are 
shown for specimens stained with FAPctrl/αSMActrl (red), FAPctrl/αSMA (blue), and FAP/αSMA(green).  Pixels 
above the threshold for αSMA-positive staining (white dotted line) are analyzed for FAP expression.  
Histograms (bottom) reveal the frequency of super-αSMA threshold pixels for FAPctrl/αSMA (blue) and 
FAP/αSMA (green).  Mean pixel intensities are shown.  C.  The graph reveals enhanced expression of FAP in 
smooth muscle cells of thin vs. thick carotid fibrous caps from single plaques taken from 5 different patients 
(mean in red, p=0.026 by paired Student’s T-Test).  
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Figure 28. Fibroblast activation protein is enhanced in thin vs. 
thick carotid fibrous caps.  A. top,  Representative 
immunofluorescent images the region displayed in FAP Cap 
images (Figure 27A) show expression of FAP (red), actin 
(green), DAPI (blue) in thick vs. thin caps (bar=20µm).  
Heatmap rendered images are shown for FAP (middle) and 
actin (bottom).  B. Quantification of FAP normalized to actin 
reveals a significant increase of FAP in thick vs. thin caps taken 
as paired samples from single plaques taken from 5 different 
patients (mean in red, n=5, p=0.035).  
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2.4.5 TOTAL FAP IS ENHANCED IN THIN VS. THICK CAROTID FIBROUS CAPS 
 
Immunofluorescent stainings and subsequent image analyses in adjacent sections reveal enhanced FAP 
expression normalized to cellular content (actin) in thin vs. thick fibrous caps (Figure 28). 
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2.5 DISCUSSION 
 
The fibrous cap is a tissue barrier between the blood stream in the vessel lumen and the thrombogenic plaque 
core, and fibrous cap thinning has been associated with plaque disruption, and atherothrombotic events.1, 12 
Therefore, specific targets which discriminate “rupture-prone” thin fibrous caps from “stable” thick fibrous caps 
may hold potential as diagnostic imaging targets in patients with carotid atherosclerosis. Here, a novel image 
analysis algorithm associates smooth muscle cell-specific FAP expression with fibrous cap thickness. 
Applying the presented two-step image analysis algorithm, we quantify cell-specific protein expression and 
associate the expression pattern of our target protein with fibrous cap thickness. After objective subtraction of 
unspecific background signals, cell-specific FAP expression could be reliably quantified. As such, this presented 
algorithm identifies enhanced expression of FAP by smooth muscle cells in thin vs. thick carotid fibrous caps. 
Congruent with other matrix-degrading collagenases such as MMPs and cathepsins, the collagenolytic activity of 
FAP may promote fibrous cap remodeling and rupture.4, 13 These findings warrant future investigations to identify a 
causal role of FAP in fibrous cap thinning in vivo. 
Taken together, our work validates a novel image analysis method to associate cell-specific protein expression 
with fibrous cap thickness. Our data suggest FAP as a potential diagnostic target in thin-capped carotid plaques. 
Moreover, the presented algorithm may be applied to identify future targets specific for thin-cap fibroatheromata, 
and to investigate cell-specific protein expression as it relates to fibrous cap thinning. 
 
2.6 ACKNOWLEDGEMENTS 
 
This work was supported by grants from the Hartmann Müller Foundation, and the University Research Priority 
Program “Integrative Human Physiology”, both at the University of Zurich. Further support was provided by the 
Special Program University Medicine (SPUM) by the Swiss National Science Foundation.  We would like to also 
thank Ursula Steckholzer for her careful preparation of the tissue specimens. 
 
  
Chapter 2    43 
2.7 REFERENCES 
 
1. Carr S, Farb A, Pearce WH, Virmani R, Yao JST. Atherosclerotic plaque rupture in symptomatic 
carotid artery stenosis. Journal of vascular surgery : official publication, the Society for Vascular 
Surgery [and] International Society for Cardiovascular Surgery, North American Chapter. 
1996;23:755-766 
2. Redgrave JN, Gallagher P, Lovett JK, Rothwell PM. Critical cap thickness and rupture in 
symptomatic carotid plaques: The oxford plaque study. Stroke. 2008;39:1722-1729 
3. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA: The Journal of the 
American Medical Association. 2005;293:855-862 
4. Brokopp CE, Schoenauer R, Richards P, Bauer S, Lohmann C, Emmert MY, Weber B, Winnik S, 
Aikawa E, Graves K, Genoni M, Vogt P, Lüscher TF, Renner C, Hoerstrup SP, Matter CM. 
Fibroblast activation protein is induced by inflammation and degrades type i collagen in thin-cap 
fibroatheromata. European Heart Journal.  
5. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. Journal of the 
American College of Cardiology. 2006;47:C13-C18 
6. Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, Rettig WJ, Gorrell MD. 
Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by 
stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29:1768-
1778 
7. Rettig WJ, Pilar G-C, Beresford HR, Oettgen HF, Melamed MR, Old LJ. Cell-surface glycoproteins 
of human sarcomas: Differentialexpression in normal and malignant tissues and cultured cells. 
Proc. Natl. Acad. Sci. USA. 1988;85:3110-3114 
8. Dippold WG, Lloyd KO, Li Lucy TC, Ikeda H, Oettgen HF. Cell surface antigens of human 
malignant melanoma: Definition of six antigenic systems with mouse monoclonal antibodies. 
Proc. Nati. Acad. Sci. USA. 1980;77:6114-6118 
9. Smith PD, McLean KJ, Murphy MA, Wilson Y, Murphy M, Turnley AM, Cook MJ. A brightness-
area-product-based protocol for the quantitative assessment of antigen abundance in 
fluorescent immunohistochemistry. Brain Research Protocols. 2005;15:21-29 
10. Landmann L, Marbet P. Colocalization analysis yields superior results after image restoration. 
Microscopy Research and Technique. 2004;64:103-112 
11. Zinchuk V, Zinchuk O, Okada T. Quantitative colocalization analysis of multicolor confocal 
immunofluorescence microscopy images: Pushing pixels to explore biological phenomena. Acta 
Histochem Cytochem. 2007;40:101-111 
12. Burke AP, Farb A, Malcom GT, Liang Y-h, Smialek J, Virmani R. Coronary risk factors and plaque 
morphology in men with coronary disease who died suddenly. New England Journal of Medicine. 
1997;336:1276-1282 
13. Chatzizisis YS, Baker AB, Sukhova GK, Koskinas KC, Papafaklis MI, Beigel R, Jonas M, Coskun AU, 
Stone BV, Maynard C, Shi G-P, Libby P, Feldman CL, Edelman ER, Stone PH. Augmented 
expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial 
shear stress colocalize with coronary atheromata with thin fibrous caps in pigs. Circulation. 
2011;123:621-630 
 
 
44 
 
CHAPTER 3 FAP IS INDUCED BY INFLAMMATION AND DEGRADES TYPE-I COLLAGEN IN 
THIN-CAP FIBROATHEROMATA 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on    
 
Fibroblast activation protein is induced by inflammation 
and degrades type I collagen in thin-cap fibroatheromata. 
Brokopp CE, Schoenauer R, Richards P, Bauer S, Lohmann 
C, Emmert MY, Weber B, Winnik S, Aikawa E, Graves K, 
Genoni M, Vogt P, Lüscher TF, Renner C, Hoerstrup SP, 
Matter CM.  
European Heart Journal. 2011; doi: 
10.1093/eurheartj/ehq519. Published online: February 2, 
2011 
 
Chapter 3    45 
3.1 ABSTRACT 
 
Background – Collagen degradation in atherosclerotic plaques with thin fibrous caps renders them 
more prone to rupture. Fibroblast Activation Protein (FAP) plays a role in arthritis and tumor formation 
through its collagenase activity. However, the significance of FAP in thin-cap human fibroatheromata 
remains unknown.  
Methods and Results – We detected enhanced FAP expression in type IV-V human aortic atheromata 
(n=12), compared with type II-III lesions (n=9; p<0.01) and healthy aortae (n=8; p<0.01) by 
immunostaining and western blot analyses. FAP was also increased in thin (<65µm) versus thick cap 
(≥65µm) human coronary fibroatheromata (n=12; p<0.01). FAP was expressed by human aortic smooth 
muscle cells (HASMC) as shown by colocalization on immunofluorescent aortic plaque stainings (n=10; 
p<0.01) and by flow cytometry in cell culture. While macrophages did not express FAP, macrophage 
burden in human aortic plaques correlated with FAP expression (n=12; R2=0.763; p<0.05). ELISAs 
showed a time- and dose-dependent upregulation of FAP in response to human TNFα in HASMC (n=6; 
p<0.01).  Moreover, supernatants from peripheral blood-derived macrophages induced FAP expression 
in cultured HASMC (n=6; p<0.01), an effect abolished by blocking tumor necrosis factor alpha (TNFα; 
n=6; p<0.01). FAP associated with collagen-poor regions in human coronary fibrous caps and digested 
type I collagen and gelatin in vitro (n=6; p<0.01). Zymography revealed that FAP-mediated collagenase 
activity was neutralized by an antibody directed against the FAP catalytic domain both in HASMC (n=6; 
p<0.01) and in fibrous caps of atherosclerotic plaques (n=10; p<0.01). 
Conclusions – FAP expression in HASMC is induced by macrophage-derived TNFα. FAP associates with 
thin-cap human coronary fibroatheromata, and contributes to type I collagen breakdown in fibrous caps. 
 
3.2 INTRODUCTION 
 
Rupture of the fibrous cap in advanced atherosclerotic plaques is a critical trigger of acute coronary 
syndromes (ACS) that may lead to myocardial infarction and sudden cardiac death.  One of the key 
events in promoting plaque instability is the degradation of the fibrous cap, which exposes the 
underlying thrombogenic plaque core to the bloodstream, thereby causing thrombosis and subsequent 
vessel occlusion.1-3 Fibrous cap rupture is facilitated by proteases which cleave type I collagen, the 
primary load-bearing molecule in fibrous caps, leading to fibrous cap thinning and destabilization.4-7 
Therefore, activated proteases, which localize to thin fibrous caps, have attracted attention as potential 
diagnostic and therapeutic targets. 
Candidate targets include matrix metalloproteinases (MMP)-2 and 9 and the cysteine protease 
cathepsin K; each of which are enhanced in both stable and unstable lesions.8-11 MMP-2 and cathepsin K 
staining reveal diffuse localization throughout the plaque, whereas MMP-9 has been shown to colocalize 
with macrophages beneath the fibrous cap.12-14 While these proteases have shown potential as markers 
of atherosclerotic plaques, their diffuse expression in all lesions warrant careful assessment of their 
targeting potential toward clinically relevant unstable plaques. An ideal protease target would be 
specific to the rupture-prone fibrous cap; a site perhaps more easily accessible by intravenously injected 
targeting agents. While MMPs and cysteine proteases have been well characterized as protease targets, 
the role of serine proteases in this context has not been investigated. 
Fibroblast activation protein (FAP) is a membrane-bound, constitutively active serine protease 
expressed by activated fibroblasts in epithelial tumor stroma, arthritis, and wound healing, but remains 
virtually undetectable in healthy tissues.15-17 FAP exhibits dipeptidyl peptidase IV activity, prolyl 
endopeptidease activity, and specificity for type I collagen and gelatin.17-19 However, the role of FAP in 
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Figure 31.  FAP is enhanced in Type IV-V 
aortic atherosclerotic plaques as shown by 
Western Blot. The graph shows a significant 
increase FAP signal compared to an all actin 
loading control in plaque-free aortae (n=8) 
compared to type II-III (n=8), and type IV-V 
plaques (n=7).  
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atherosclerosis is unknown. The aim of this study was to characterize FAP expression in human 
atherosclerosis and examine its association with features of plaque instability. Moreover, we sought to 
determine the mechanism of FAP induction, its downstream effects, and the capacity of a neutralizing 
FAP-specific antibody. 
 
3.3 METHODS 
 
3.3.1 AORTIC AND CORONARY ARTERY SPECIMENS 
 
Ascending aortic plaque biopsies were placed into sterile Dulbecco’s Modified Eagle Medium (DMEM; 
Gibco, Carlsbad, CA), pre-chilled to 4°C, and transferred on ice to the laboratory and frozen in Optimal 
Cutting Temperature Compound (Tissue-Tek, Torrance, CA) for tissue zymography. Coronary arteries 
were obtained from patients that died after an acute myocardial infarction. Approval from the local 
Ethics Committee was obtained for collections of all patient specimens. 
 
3.3.2 CHARACTERIZATION OF ATHEROSCLEROTIC PLAQUES 
 
Biopsies of normal and plaque bearing ascending aortae were obtained from patients undergoing 
surgical aortic valve replacement secondary to aortic stenosis (n = 20, age (y): 63 ± 14.5, BMI: 27.8 ± 5.4, 
diabetes mellitus 3/20; CRP (mg/L): 2.1 ± 1.8, Triglycerides (mmol/L): 2.2 ± 1.6, LDH (IU/L): 218.9 ± 37.8). 
Aortic plaques were sectioned and graded according the American Heart Association (AHA) criteria20, 21 
using Movat pentachrome, Oil-Red-O, anti-CD68, and von Kossa staining (data not shown). Coronary 
arteries were obtained from patients that died after an acute myocardial infarction and embedded in 
paraffin for sectioning. Collagen in coronary artery plaques was 
characterized by Masson staining. Fibrous caps were identified as 
the collagen-rich tissue separating the lumen and the necrotic core.2 
Plaques with a minimum fibrous cap thickness of less than 65 µm 
were classified as thin-cap, whereas plaques with a fibrous cap 
thickness equal or greater than 65 µm were classified as thick-cap 
atheromata.2  
 
3.3.3 FAP IMMUNOBLOTTING 
 
Characterized plaques and plaque-free aortic tissue samples were 
snap-frozen in liquid nitrogen, homogenized and blotted according 
to standard procedures. The following antibodies were used:  FAP 
was labeled using rabbit A246, actin (Figure 31) was labeled using a 
polyclonal rabbit anti–human antibody [Sigma-Aldrich]) and αSMA 
was identified using a rabbit polyclonal against alpha-smooth muscle 
actin (αSMA; Ab5694; Abcam). Densiometry was performed using a 
FluorChem Q Imaging System (Alpha Innotech).  
 
3.3.4 IMMUNOFLUORESCENCE AND IMMUNOHISTOCHEMISTRY 
 
Cross sections from human ascending aortae (10 µm thickness) and paraffin-embedded sections of 
coronary plaques  (4 µm thickness) were mounted on glass slides. Paraffin-embedded coronary sections 
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were labeled with A246 and subsequently by Cy5-labeled secondary goat anti-mouse IgG (115-175-146; 
Jackson ImmunoResearch).  FAP colocalization with macrophages, endothelial cells, and smooth muscle 
cells was determined using a rabbit antibodies directed against CD68 (SC-9139; Santa Cruz, Santa Cruz, 
CA), von Willebrand factor (vWF; F3520; Sigma-Aldrich, Carlsbad, CA),  alpha-smooth muscle actin 
(αSMA; Ab5694; Abcam), or type I collagen (Ab292; Abcam); subsequent fluorescent labeling was 
performed using a Cy3-labeled anti-rabbit IgG (111-165-144; Jackson ImmunoResearch) in three 
adjacent sections of each biopsy specimen.  DAPI (D9542; Sigma-Aldrich) was used for fluorescent 
counterstaining of nuclei.  Isotype control antibodies were used to address antigen-binding specificity.  
Stained samples were cover-slipped with Tris-buffered glycerol (a 3:7 mixture of 0.1 M Tris-HCl at pH 9.5 
and glycerol supplemented with 50 mg/mL n-propyl-gallate). 
Antigen retrieval in paraffin-embedded sections of coronary plaques was performed after 20 min 
incubation in 95ºC retrieval buffer (2 mM Sodium Citrate, pH 7.6). FAP was stained using a rabbit 
polyclonal antibody raised against the catalytic insert of FAP (A246; Ab28246; Abcam, Cambridge, MA) 
and a rabbit isotype control (Ab37415; Abcam). Cryosections of aortic plaques were fixed in ice-cold 
acetone for 5 min and stained using a mouse monoclonal against FAP (F19, Provided by Sloan-Kettering 
Institute, New York, NY) and the appropriate mouse isotype control (401401; BioLegend, San Diego, 
CA).22, 23  Primary antibodies were detected with biotin-labeled goat anti-mouse (115-066-003; Jackson 
ImmunoResearch, West Grove, PA) and biotin-labeled goat anti-rabbit (111-066-003; Jackson 
ImmunoResearch) and stained using an ABC staining kit (Vector Labs, Burlingame, CA). 
 
3.3.5 IMAGE ANALYSIS 
 
For low power imaging at spatial resolutions above 1 µm/pixel, we used a fluorescent microscope 
(DM60000B; Leica, Wetzlar, Germany) equipped with a fluorescent camera (DFC350 FX; Leica). 
Colocalization analyses were performed at higher magnifications using a multichannel confocal 
microscope (TCS SP2, Leica) on a single optical plane. 
Single-channel fluorescent images (nine images per section in three adjacent sections) of aortic tissue 
sections were taken at constant camera settings in tagged image file format (TIFF) at a binary pixel 
intensity between 0-255.  In each group, additional adjacent tissue sections were stained with isotype 
control antibodies to determine the background threshold.  The background intensity threshold for each 
channel was set at the intensity under which 95% of the pixels emitted in control staining. 24, 25 Pixels 
below the background intensity threshold were excluded from quantification.25 The remaining pixels 
were summed and divided by the total number of pixels to calculate the mean pixel intensity. Positive 
pixels were summed to calculate positive area using image analysis software by Matlab (Mathworks, 
Novi, MI). 26 Quantitative colocalization analyses were performed using a confocal microscope at high 
resolution on a single plane.  Two TIFF images were captured from distinct fluorescent channels on each 
tissue section, and background signal was subtracted as previously described. Colocalization coefficients 
were calculated as the sum of FAP-positive pixels, which colocalized with pixels positive for cell-specific 
markers.27, 28 
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Figure 32.  Membrane-bound FAP is detected by 
indirect ELISA on cell membranes. The graph shows a 
significant increase FAP signal in F19-labelled huFAPs 
compared with HEKs or IgG labeled controls 
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3.3.6 CELL CULTURES 
 
Human aortic endothelial cells (HAEC) were isolated from biopsies of ascending aortae without 
macroscopic lesions obtained from patients undergoing operations for valve repair, human aortic 
smooth muscle cells were purchased (HASMC; Promocell); peripheral blood-derived monocytes were 
isolated from healthy subjects. Foam cells were generated by stimulating macrophages with 100 µg/mL 
of oxidized low-density lipoprotein (BT-910; BioConcept, Allschwil, Switzerland) for 48 h in Serum-Free 
Macrophage Medium (SFM; Gibco). Lipid uptake was assessed by Oil-red-O staining (O0624; Sigma-
Aldrich).  
For endothelial cell isolation, aortic lumens were washed with PBS and incubated in DMEM containing 
collagenase type 2 (350 U/mL; Worthington, Lakewood, NJ) for 30 min, and agitated gently to dissociate 
the endothelium from the vessel wall.  Endothelial cells were further purified by magnetic bead 
separation against CD34 (130-046-702; Miltenyi Biotec, Gladbach, Germany). HAEC were expanded in 
endothelial cell growth medium (EGM2; Gibco) and characterized by FACS analysis for vWF expression 
(>98%). To isolate phagocytic monocytes, 50 mL of peripheral venous blood was collected from healthy 
probands in EDTA collection tubes, diluted 2x in Hank’s buffered salt solution and spun on a Ficoll 
gradient (20 min, 400 G, 24°C).  
Monocytes were selected from the buffy coat by magnetic bead sorting for CD14 (130-050-201; 
Miltenyi Biotec), to yield a final purity over 94% (FACS against CD64).  Monocytes were differentiated 
into macrophages in polystyrene six well plates over seven days in RPMI-1640 (Gibco) containing 10% 
heat-inactivated, low-endotoxin fetal bovine serum (Gibco) and 50nM recombinant human macrophage 
colony stimulating factor (AF-300-03; Peprotech, Rocky Hill, NJ), replacing the media every 48 h.  
Macrophage differentiation was validated using anti-CD68 FACS analysis.  FAP was measured in all cell 
types using F19 in unfixed cells and a Cy5-conjugated secondary antibody for FACS analyses, and the 
appropriate murine IgG isotype control antibody. 
 
3.3.7 FAP INDUCTION ASSAYS 
 
Peripheral blood-derived macrophages were incubated for 48 h in SFM (2mL/well in a 6 well plate) 
and the supernatant was sterile filtered, aliquoted, and frozen at -80ºC.  Purchased human aortic 
smooth muscle cells (HASMC; Promocell) were validated by FACS analyses for αSMA (purity>96%), and 
plated at passage 4 into a 96-well black cell culture test plate at a density of 5x104 cells/cm2 in DMEM 
(10938; Gibco) supplemented with 10% Fetal Calf Serum 
(3302-P250302; PAN Biotech, Aidenbach, Germany) and 
allowed to attach for 24 h before rendered quiescent 
overnight in Advanced DMEM (12491-015; Invitrogen, 
Carlsbad, CA) with 1% bovine serum albumin (starvation 
medium). Quiescent HASMCs were treated with starvation 
media supplemented with 3, 5, 10, 20, 40% macrophage-
conditioned SFM for 48 h. To determine the effects of TNFα on 
FAP expression, quiescent HASMCs were treated with 
starvation media supplemented with 20% macrophage-
conditioned SFM and a TNFα-neutralizing antibody (Ab6671; 
Abcam) or an IgG isotype control (Ab27478; Abcam) antibody. 
Recombinant human TNFα (300-01A; Peprotech) was used to 
induce FAP expression in quiescent HASMC in a dose- and 
time-dependant manner. For quantifications, cells were 
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Figure 34. A246 reduces gelatinase activity of recombinant human FAP (rhuFAP) and HASMC in vitro.  
A. The graph reveals dose-dependent inhibition of rhuFAP gelatinase activity by A246 (n=6/group; ** = 
p<0.01; * = p<0.05).  B. The graph reveals dose-dependent inhibition of FAP in HASMC (n=6/group; ** 
= p<0.01; * = p<0.05).  
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Figure 33. rhuFAP degrades DQ-collagen. The graphs 
shows rhuFAP cleavage of DQ-gelatin (n=6/group) in 
vitro.  
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washed with PBS, fixed in 4% formalin for 30 min, and labeled against FAP with F19.  Cultures were 
enzymatically labeled using a Horseradish Peroxidase ELISA kit (Anaspec, Fremont, CA) and the 
enzymatic product quantified with a fluorescent plate reader.  Background values were subtracted, and 
all values were normalized to untreated/unconditioned control groups. 
Validation of the FAP ELISA was performed using HEK293 as a negative control, and HEK293 cells 
stably transfected with an FAP plasmid as a positive control.  An unspecific murine IgG antibody was 
used as a negative control detection antibody and the anti-FAP F19 antibody was used as a positive 
control antibody (Figure 32).           
 
3.3.8 ZYMOGRAPHY ASSAYS 
 
In situ zymography was performed on (5µm) cryosections of human aortic atherosclerotic 
plaques which had been stained against FAP using non-inhibitory F19 and Cy5 labeled secondary 
antibody, and then treated with A246 or an isotype control at 50 nM concentration overnight.17 Treated 
and untreated sections were then mounted in warm 1% Agarose in PBS with 10% direct quenched type I 
collagen from bovine skin (D12060; Invitrogen) and imaged after 2 h at 37ºC by confocal microscopy.  
For quantification, background signals were subtracted from 
isotype control images and pixels which were positive for both 
FAP cleaved Type I collagen were quantified as the average of 
nine images from three adjacent sections per biopsy. 
Direct-quenched porcine gelatin (DQ gelatin; D12054; 
Invitrogen) was diluted to a final concentration of 100 µg/mL in 
reaction buffer (0.5 M Tris-HCl, 1.5 M NaCl, 50 mM CaCl2, and 2 
mM sodium azide at pH 7.6) and 0, 10, 20, 40 nM of 
recombinant human FAP in a black 96-well plate.  Cleaved 
gelatin was quantified, at 0.5, 8, and 24 h, and background 
fluorescence subtracted (Figure 33). 
 A246 raised against FAP’s catalytic insert and a matching 
isotype control IgG (Ab27478; Abcam) were added to 20 mM 
recombinant human FAP and 100 µg/mL DQ gelatin or DQ type 
I collagen in reaction buffer 
and analyzed after 24 h, to 
determine blocking efficacy. 
A246 is a rabbit polyclonal 
raised against an FAP-specific 
peptide, immunogen affinity 
purified, and recognizes 
fibroblast activation protein 
specifically, but not other 
dipeptidyl peptidases family 
members (Abcam; Ab28246).   
Confluent HASMC at passage 
4 were treated with A246 or 
an antibody control for 30 
min, washed with PBS, and 
then placed under 100 μL of 100 μg/mL DQ gelatin in reaction solution for 4 h before fluorescence 
analysis with a plate reader (Figure 34).  
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3.3.9 FAP-MEDIATED TYPE I COLLAGEN DEGRADATION ASSAYS 
 
To evaluate the FAP-mediated type I collagen-specific cleavage, full-length native human type I 
collagen isolated from human placenta (purity >90%) was used (288; Yo Proteins). Type I collagen 
(100ng/mL) was treated with recombinant human FAP (200nM) for 18 h at 37°C in PBS (pH = 7.2) and 
compared to an untreated collagen control. A246 (50ng/mL) was added to the solution and compared to 
an isotype control antibody IgG (Ab27478; Abcam) to validate the neutralizing capacity of A246.  
Samples were separated by gel electrophoresis and visualized by silver staining (ProteoSilver Silver Stain 
Kit, Sigma). 
 
3.3.10 STATISTICAL ANALYSES 
 
Histological and cell culture results were compared using one-way ANOVA and associations calculated 
by Pearson’s correlation coefficient. Student’s T-test was used for comparisons of zymography. All 
statistical analyses were performed using MatLab (Version, R2007b). Data are presented as mean±SD. 
Significance was accepted at the level of p<0.05. 
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Figure 35. FAP expression is enhanced in human atherosclerotic aortic plaques. A, Movat and FAP stainings show cross-sections of 
representative plaque-free aortae and Type IV aortic atherosclerotic plaques (L=lumen, M=media, P=atherosclerotic plaque; bar=400 
µm). Dotted boxes indicate regions of interest in adjacent sections at high magnification (bar=50 µm). B, Western blot analysis of FAP 
normalized to αSMA in plaque-free aortae (n=8), type II-III plaques (n=8), and type IV-V plaques (n=7) show a significant increase in FAP 
in advanced type IV-V plaques by immunoblot densitometry. C, Immunofluorescent stainings in representative tissue sections of plaque-
free aortae, type II-III plaque, and type IV plaque show FAP expression in red (DAPI in blue; bar=50 µm). D, The graph reveals a 
significant increase in FAP expression in Type II-III aortic plaques (n=9) and in Type IV-V plaques (n=12) compared with plaque-free 
aortae (n=8).  
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3.4 RESULTS 
 
3.4.1  FAP EXPRESSION IS ENHANCED IN ADVANCED HUMAN AORTIC PLAQUES 
 
Immunofluorescent stainings for FAP in adjacent cryosections revealed enhanced expression of FAP in 
fibroatheromata vs. plaque-free aortae (Figure 35A). Positive staining for FAP was virtually absent in 
healthy ascending aortae, whereas a step-wise increase was observed in Type II-III and Type IV-V 
plaques by western blot analyses (Figure 35B) and quantitative image analysis (Figure 35C-D). 
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Figure 36. FAP expression in human aortic plaques colocalizes with smooth muscle cells, but not with macrophages or endothelial 
cells. A, Overlays of confocal images of FAP (red) and DAPI (blue) with cell-specific stainings of αSMA, CD68, and vWF (green) in 
representative sections illustrate FAP colocalization (arrows) with smooth muscle cells (bar=20 µm). B, The graph quantifies an 
increased colocalization of FAP with smooth muscle cells (αSMA), compared with endothelial cells (vWF) and macrophages (CD68) in 
type IV-V atherosclerotic plaques (n=10). 
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3.4.2  FAP IS EXPRESSED BY SMOOTH MUSCLE CELLS IN ADVANCED HUMAN AORTIC 
PLAQUES 
 
To characterize FAP-expressing cell types in human atherosclerotic plaques, we performed immunofluorescent 
co-stainings of FAP in macrophages (identified as CD68-positive cells), smooth muscle cells (αSMA-positive cells), 
and endothelial cells (vWF-positive cells) (Figure 36A). Confocal image analyses revealed FAP expression by 
smooth muscle cells, but not by macrophages or endothelial cells (Figure 36B). 
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3.4.3  SMOOTH MUSCLE CELLS EXPRESS FAP IN-VITRO 
 
To validate FAP expression by vascular cells in vitro, we performed FACS analyses of FAP in HASMC (αSMA-
positive cells), HAEC (vWF-positive cells), peripheral blood derived-monocytes (CD64-positive), macrophages 
(CD68-positive), and foam cells (Oil-Red-O-positive macrophages). FACS analyses revealed high constitutive FAP 
expression in HASMC, slight expression in HAEC, but no expression by peripheral blood-derived monocytes, 
macrophages or foam cells (Figure 37). 
 
 
 
  
Figure 37. FAP is constitutively expressed in cultured 
human aortic smooth muscle cells (HASMC) and 
endothelial cells (HAEC), but not in peripheral blood-
derived monocytes (PBM), macrophages (MΦ), or foam 
cells. FACS analyses and Oil-Red-O staining of peripheral 
blood derived-macrophages laden with oxidized low-
density lipoprotein (oxLDL) characterize cells populations 
(left) and their respective FAP expression (right).  
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Figure 38. FAP expression is enhanced in thin-cap versus thick-cap human coronary fibroatheromata. A, 
Masson staining shows collagen-rich thick (658 µm) versus thin (45 µm) fibrous caps (L=lumen, FC=fibrous 
cap, NC=necrotic core; bar=1 mm).  FAP immunohistochemistry and immunofluorescence (intensity scale; 
bar=50 µm) shows FAP expression in representative thin vs. thick caps. Dotted boxes indicate regions of 
interest in adjacent sections at high magnification.  B, The graph reveals a significant increase in FAP 
expression in thin vs. thick fibrous caps (n=12 each).  
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3.4.4  FAP EXPRESSION IS ENHANCED IN THIN-CAP VERSUS THICK-CAP HUMAN 
CORONARY ATHEROMATA 
 
In order to determine the association of FAP with coronary fibrous cap thickness, we stained collagen applying 
the Masson method (stains collagen in blue) in rupture-prone human coronary arteries obtained from patients 
that died after myocardial infarction. Based on fibrous cap thickness these specimens were characterized as thin-
cap (<65 μm) or thick-cap (≥65 μm) fibroatheromata. Immunohistological and immunofluorescent stainings and 
subsequent confocal image analyses in adjacent sections revealed enhanced FAP expression in thin compared with 
thick fibrous caps (Figure 38). 
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Figure 39. FAP expression correlates with macrophage burden in human aortic 
plaques. A, Confocal immunofluorescent photomicrograph of an aortic fatty 
streak reveals FAP expression (red) adjacent to macrophages (CD68; green) at 
low (phase-contrast, white; bar=100 μm) and high magnification (bar=25 μm). 
B, Movat staining (bar=400 μm), FAP, or macrophage (CD68) 
immunofluorescent stainings in plaque-free aortae, Type II, and Type V 
atherosclerotic plaques show enhanced FAP expression with increasing 
macrophage burden (bar=50 µm). C, Comparisons of FAP and macrophage 
expression in serial adjacent sections from aortic plaques demonstrate a 
significant positive correlation (R2=0.763; n=12; p<0.05); AU, arbitrary units.  
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3.4.5  FAP ASSOCIATES WITH MACROPHAGE BURDEN IN HUMAN AORTIC 
ATHEROSCLEROTIC PLAQUES 
 
Immunofluorescence stainings revealed FAP expression in medial cells adjacent to macrophages in aortic fatty 
streaks (Figure 39A). To characterize the relationship between FAP and inflammation, we compared FAP and 
macrophage immunofluorescent signal intensity in human aortic plaques (Figure 39B). We observed a positive 
correlation between macrophage burden and FAP expression with plaque progression (R2=0.763; n=12; Figure 
39C). 
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3.4.6  MACROPHAGE-DERIVED TNFα INDUCES FAP EXPRESSION IN SMOOTH MUSCLE 
CELLS 
 
To elucidate a signaling mechanism between macrophages and FAP expressing HASMC, we exposed HASMC to 
macrophage-conditioned media for 48 h to simulate conditions applicable to plaque inflammation. Cultured 
HASMC showed a dose-dependent increase in FAP expression in response to the macrophage-conditioned media 
with a maximal effect observed at 20% media concentration (Figure 40A) after 48 h. This effect was abolished 
when macrophage-conditioned media was supplemented with a TNFα-neutralizing antibody (Figure 40B). To 
confirm this paracrine effect of TNFα on FAP expression, experiments were repeated using recombinant human 
TNFα. TNFα-mediated FAP expression was observed in a dose- and time-dependent manner, with a maximum 
response at 30 ng/mL after 48 h (Figure 40C-D). 
 
 
  
 
Figure 40. Macrophage-derived TNFα induces FAP expression in HASMC. A, Macrophage-
conditioned supernatant induces FAP in HASMC in a concentration-dependent manner 
following 48 h exposure (n=6).  B, Using the same macrophage-conditioned medium, TNFα-
blocking antibody (Ab6671) decreases FAP expression by 40% in HASMC compared with an 
isotype control antibody (n=6). C, Recombinant human TNFα induces FAP in HASMC in a dose-
dependent manner after 48 h incubation (n=6). D, Recombinant human TNFα induces FAP in 
HASMC in a time-dependent manner (30 ng/mL). AU, arbitrary units (*=p<0.05, **=p<0.01).  
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Figure 41. Type I collagenase activity is inhibited in human 
aortic fibrous caps by the FAP-blocking antibody A246. A, 
Movat staining of a fibrous cap in human aortic plaque. The 
region of interest (black box) is shown at higher 
magnification in an adjacent section stained for FAP (red), 
type I collagen (green), and overlay (DAPI=blue; bar=150 
µm). B, Confocal images of in situ zymography show FAP 
(red) and cleaved DQ type I collagen (green) in fibrous caps 
shown by Movat (7A) of aortic plaque treated with a control 
IgG antibody or neutralizing antibody A246 (bar=10 μm). C, 
The graph reveals a significant reduction of cleaved type I 
collagen colocalized with FAP expression by in situ 
zymography (n=10/group). D, Type I Collagenase activity of 
rhuFAP and the neutralizing capacity of A246 was 
demonstrated by incubation of native human type I collagen 
with rhuFAP in the presence of inhibiting or isotype control 
antibodies (Lanes 1 rhuFAP, 2 collagen, 3 rhuFAP + collagen, 
4 rhuFAP + collagen + A246, 5 rhuFAP + collagen + isotype 
control antibody, 6 molecular weight marker).  
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3.4.7  FAP IS INHIBITED BY AN FAP NEUTRALIZING ANTIBODY IN FIBROUS CAPS 
 
Immunofluorescence analyses revealed enhanced FAP expression in Type I collagen-poor regions of aortic 
fibrous caps (Figure 41A). Aortic fibrous caps treated with an IgG control antibody showed a colocalization of FAP 
with cleaved DQ type I collagen, whereas Ab246-treated plaques demonstrated a significantly reduced 
colocalization of FAP with type I collagenase activity (Figure 41B). Confocal image analyses revealed that A246-
treated fibrous caps exhibited decreased cleaved type I collagen at sites of FAP expression (Figure 41C). Type I 
collagenase activity of rhuFAP and the neutralizing capacity of A246 were demonstrated by incubation of native 
human type I collagen with rhuFAP in the presence of inhibiting antibody or isotype control (Figure 41D).  
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3.5 DISCUSSION 
 
The fibrous cap of an atherosclerotic plaque is essential for separating the blood stream in the vessel 
lumen from the its thrombogenic necrotic core. The mechanical strength of the fibrous cap is provided 
primarily by type I collagen, which is degraded by MMPs and cysteine proteases, both of which are 
associated with plaque instability and occurrence of acute thrombotic events.29-33 
This study links the constitutively active serine protease FAP to plaque progression and fibrous cap 
thinning and provides evidence that: (1) FAP expression is enhanced in human aortic atheromata and in 
fibrous caps of thin-cap coronary plaques, (2) FAP is expressed in HASMC and its expression correlates 
with macrophage burden, (3) FAP expression is induced in HASMC by macrophage-derived TNFα via 
paracrine signaling, (4) FAP cleaves collagen in fibrous caps of human atheromata, and (5) FAP-mediated 
type I collagenase activity is inhibited by a FAP-neutralizing antibody. 
Numerous studies implicate matrix-degrading collagenases such as MMP1, 2, and 9 as well as cysteine 
proteases such as cathepsins S and K in vascular remodeling and plaque rupture.13, 30, 34 Our findings 
provide evidence that FAP is the first known smooth muscle cell-derived serine protease involved in 
collagen degradation in human atherosclerosis. FAP expression was particularly enhanced in fibrous 
caps of thin-cap human coronary plaques isolated from patients that died after myocardial infarction. 
Indeed, thin fibrous caps (<65µm) have been associated with sudden cardiac death.2, 35 The type I 
collagenase activity of FAP is demonstrated by both FAP-mediated collagenolysis in fibrous caps and the 
association of FAP with collagen-poor fibrous cap tissue in image analyses. These observations underline 
the potential clinical relevance of FAP as a diagnostic and / or therapeutic target in patients with plaques 
prone to rupture, i.e. patients at risk for ACS or stroke. 
Inflammation constitutes a key feature of plaque vulnerability and inflammatory processes have been 
shown to induce collagenases in atherosclerotic plaques.4, 36, 37 Consistent with this paradigm, we 
demonstrate that FAP expression in HASMC is associated with macrophage burden in intermediate and 
advanced human atherosclerotic plaques. FAP was not expressed by macrophages. However, 
macrophage-derived TNFα induced a dose- and time-dependent increase in FAP expression in cultured 
smooth muscle cells. These data indicate that a paracrine inflammatory pathway can induce FAP 
expression in smooth muscle cells. Thereby, our findings contribute to a growing body of evidence that 
supports the notion of inflammation-induced collagenase expression in atherosclerosis.6, 11, 29, 38 Such 
findings could motivate future studies to investigate putative atheroprotective interventions involving 
either key anti-inflammatory mechanisms, such as the TNFα pathway, collagen-degrading enzymes 
themselves such as FAP, or both.  
In addition to its expression in smooth muscle cells, we detected constitutive FAP expression in human 
aortic endothelial cells in vitro. Endothelial activation is a critical step in atherogenesis.39 Activated 
endothelial cells express fibrous cap-degrading collagenases, and have also been shown to act in concert 
with fibrous cap-degrading smooth muscle cells.5, 32, 40 Indeed, the observed capacity of endothelial cells 
to express FAP in-vitro supports the notion of a coordinated remodeling of the fibrous cap by both 
endothelial and smooth muscle cells. Furthermore, by recruiting blood-borne inflammatory cells to the 
plaque, activated endothelial cells may also enhance macrophage-derived cytokine release, activate 
smooth muscle cells, and thus induce FAP expression and / or activity. 
Distinct from MMPs FAP combines several unique properties: MMPs exhibit diffuse expression 
throughout both intermediate and advanced atherosclerotic plaques.14 In contrast, FAP expression is 
associated specifically with thin-cap atheromata. Moreover, MMP activity is modified by tissue 
inhibitors of metalloproteinases (TIMPs), whereas no natural inhibitors of the constitutively active FAP 
are identified. It is therefore plausible that FAP expression associates with its activity, rendering FAP a 
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potential diagnostic target. Furthermore, we demonstrate that FAP is mainly expressed in activated 
smooth muscle cells in thin fibrous caps of advanced atherosclerotic plaques. Given its localization in the 
fibrous cap close to the blood stream, FAP may be more accessible than MMPs by circulating targeting 
agents. 
Taken together, we found that FAP expression is induced by macrophage-derived TNFα in human 
aortic smooth muscle cells, associates with thin-cap human coronary plaques, and contributes to type I 
collagen breakdown in fibrous caps. Thus, FAP expression in thin-cap coronary plaques and endothelial 
cells renders this target attractive for further investigation in patients with ACS. Along this line, we plan 
to investigate whether soluble FAP may be a biomarker for ACS. Moreover, our present findings 
demonstrate that FAP-mediated collagenolysis is induced by inflammatory cues and may be blocked by 
neutralizing antibodies. At the experimental level, studies using genetic or pharmacological modulation 
of FAP will shed light onto the causal role of FAP in atherogenesis and its potential use as a target in 
atherosclerosis and other inflammatory diseases such as rheumatoid arthritis and tumor formation. 
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CHAPTER 4 FAP IS ENHANCED IN ATHEROTHROMBOSIS AND ACCELERATES BLOOD COAGULATION  
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4.1 ABSTRACT 
 
Background – Fibroblast Activation Protein (FAP) contributes to plaque disruption via its collagenase 
activity and plays a known role in impaired fibrinolysis.   However, the significance of FAP in 
atherothrombosis and acute coronary syndromes (ACS) remains unknown. 
Methods and Results – We detected enhanced FAP expression in occluding human coronary thrombi 
compared to peripheral blood by immunohistochemistry and RT-PCR (n=6; p<0.01).  Confocal image 
analysis revealed FAP expression by thrombus neutrophils.  FAP was increased in coronary thrombus 
neutrophils (n=6; p<0.01), compared to peripheral blood neutrophils, but not in monocytes or 
leukocytes.  FAP expression could also be detected in thin-cap coronary fibroatheromata. Acutely 
formed coronary thrombi showed increased expression of FAP compared to chronic peripheral artery 
derived thrombi (p<0.01).  Native rotational thromboelastometry indicated a dose and time-dependant 
effect of FAP on accelerated blood coagulation and clot thickness.   
Conclusions – FAP is expressed by neutrophils during acute coronary thrombus formation. FAP also 
associates with the endothelium in coronary thin-cap fibroatheromata, and contributes to 
hyperthrombosis. 
 
4.2 INTRODUCTION 
 
Atherothrombosis is characterized by atherosclerotic lesion disruption superimposed with thrombus 
formation, and is the primary cause of myocardial infarction.  A key trigger of atherothrombosis is 
disruption of the fibrous cap, which exposes thrombogenic plaque components to the bloodstream. 
Therefore, atherothrombosis is governed by factors involved in both plaque rupture and blood 
coagulation.   
While collagenases play a hallmark role in fibrous cap destabilization and plaque rupture, they do not 
directly contribute a hyperthrombogenic state in the blood.1-4 Atherosclerotic plaque-derived factors 
involved in systemic hyperthrombosis have therefore also drawn attention, particularly in cases of 
atherothrombosis due to superficial intimal erosion.  Circulating tissue factor for example has been 
associated with increased blood thrombogenicity in patients with unstable angina.5  However the role of 
tissue factor in atherosclerotic plaque rupture and superficial intimal erosion per se is minimal.  Still, 
proteases which promote plaque rupture while simultaneously accelerating blood thrombosis may hold 
potential as diagnostic and therapeutic targets. 
Fibroblast activation protein (FAP) is a constitutively active serine protease that associates with thin-
cap coronary fibroatheromata. FAP contributes to fibrous cap destabilization via its collagenolytic 
activity, and also to hyperthrombosis via activation of α2-Antiplasmin; a coagulation factor which inhibits 
plasmin-mediated thrombolysis.6, 7  The aim of this study was to characterize FAP expression in human 
coronary atherothrombosis and to also determine the causal role of FAP in accelerated blood 
coagulation.  
 
4.3 METHODS 
 
4.3.1  THROMBUS AND PERIPHERAL BLOOD SPECIMENS 
 
Thrombi from the coronary and femoral arteries were aspirated from patients who suffered a 
myocardial infarction or peripheral artery occlusive disease, respectively.  5mL of peripheral blood was 
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drawn from each patient into the citrated tube prior to thrombus aspiration.  The thrombi and blood 
specimens were placed in phosphate buffered saline and transferred to the laboratory for immediate 
processing.  Thrombi analyzed by immunohistochemistry were fixed for 24hr in formalin, specimens for 
immunohistochemistry were embedded for cryosectioning and frozen @ -80°C, and specimens for RT-
PCR analysis were snap frozen. 
 
4.3.2  IMMUNOHISTOCHEMISTRY 
 
Cross sections from human paraffin-embedded thrombi and peripheral blood sections (4 µm 
thickness) of coronary plaques  were mounted on glass slides.  Antigen retrieval in paraffin-embedded 
sections of coronary thrombi and peripheral blood was performed after 20 min incubation in 95°C 
retrieval buffer (2 mM Sodium Citrate, pH 7.6). FAP was stained using a rabbit polyclonal antibody raised 
against the catalytic insert of FAP (A246; Ab28246; Abcam, Cambridge, MA) and a rabbit isotype control 
(Ab37415; Abcam).  CD31 was stained using a mouse monoclonal antibody (303108; Biolegend) and 
matching isotype control (400123; Biolegend).  Primary antibodies were detected with biotin-labeled 
goat anti-mouse (115-066-003; Jackson ImmunoResearch, West Grove, PA) and biotin-labeled goat anti-
rabbit (111-066-003; Jackson ImmunoResearch) and stained using an ABC staining kit (Vector Labs, 
Burlingame, CA). 
 
4.3.3  REAL-TIME POLYMERASE CHAIN REACTION 
 
Thrombi and peripheral blood were lysed in RLT buffer, and total RNA was isolated using an RNeasy 
Mini kit (Qiagen). Total RNA was reverse transcribed using random hexamers and MultiScribe reverse 
transcriptase (Applied Biosystems). Non–reverse-transcribed samples were used as negative controls. 
Single-reporter real-time PCR was performed using the ABI Prism 7700 Sequence Detection system 
(Applied Biosystems).  The primer sequence for FAP was forward 5’-CAAGAA-TGT-TTC-GGT-CCT-GT-3’ 
and reverse 5’-GTC-TGCCAG-TCT-TCC-CTG-AA-3’.  Eukaryotic 18S ribosomal RNA, measured with a 
predeveloped primer/probe system (Applied Biosystems), served as endogenous controls for relative 
quantification. 
 
4.3.4 IMMUNOFLUORESCENCE 
 
Cryosections of aortic plaques were fixed in ice-cold acetone for 5 min and stained using a mouse 
monoclonal against FAP (F19, Provided by Sloan-Kettering Institute, New York, NY) and the appropriate 
mouse isotype control (401401; BioLegend, San Diego, CA).8, 9  F19 was then labeled with a Cy5 goat 
anti-mouse IgG (115-175-146; Jackson ImmunoResearch).  Sections were then washed in PBS and  
stained for granulocytes, monocytes, and T-Lymphocytes with a FITC-labelled mouse antibodies directed 
against CD66b (555724, BD Pharmingen), CD14 (555397, BD Pharmingen),  CD3 (555332, BD 
Pharmingen).  Non-specific staining was addressed using a FITC labeled mouse isotype control (555748, 
BD Pharmingen) antibody.  DAPI (D9542; Sigma-Aldrich) was used for fluorescent counterstaining of 
nuclei.  Isotype control antibodies were used to address antigen-binding specificity.  Stained samples 
were cover-slipped with Tris-buffered glycerol (a 3:7 mixture of 0.1 M Tris-HCl at pH 9.5 and glycerol 
supplemented with 50 mg/mL n-propyl-gallate). Colocalization analyses were performed using a 
multichannel confocal microscope (TCS SP2, Leica) on a single optical plane. 
 
4.3.5  NATIVE THROMBOELASTOMETRY 
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Peripheral blood was harvested from healthy probands into citrate collection tubes.   All healthy 
probands were shown to have plasma FAP levels of less than 5ng/mL by ELISA.  Recombinant human 
FAP (Enzo, BML-SE409) was diluted into sterile saline and added to proband blood such that the final 
concentration of rhuFAP in the blood was 0, 0.175, 1.75, and 3.5µg/mL of blood.  NATAM (Axon Lab, 
Baden-Dättwil, Switzerland) analysis was performed according to the manufacturer’s instructions by 
using STAR-TEM reagent after incubation times of 0, 2.5, and  5hrs before beginning the analysis.  All 
analyses were performed on the same machine. 
 
4.3.6  FLOW CYTOMETRY 
 
Peripheral blood (1mL) and thrombi were placed into 1mL of Acutase with 50 µL Actilyse, and shaken 
gently at 37°C for 1 hr. Cell aggregates were further dissociated by sifting through a cell strainer (40µm 
pore size) using the soft rubber from a syringe. Both samples were then spun at 400 G for 5 min and the 
supernatant removed.  Cell pellets were then resuspended in FACS buffer (PBS with 1% FCS and 5 mM 
EDTA) with 1 µg/mL for Fc receptor blocking agent and incubated for 30 min at 4°C. Cells were 
subsequently labeled with fluorescently tagged antibodies presented in Table 1, and in the combinations 
presented in Table 2.  Representative cell population gatings and histograms are shown in Figures 42-48.   
 
  
 
 
 
 
 
 
 
 
                         
Table 1.  Antibodies used for flow cytometry.  
Table 2.  Antibody profiles for cell population gating.  
 
Antigen Label Source
CD66b FITC 555724 BD Pharmingen
CD45 PER-CP 345809 BD Pharmingen
CD14 FITC 555397 BD Pharmingen
CD125 PE 555902 BD Pharmingen
CD3 FITC 555332 BD Pharmingen
FAP Alexa 647 ATCC-CRL-2733
IgG control Alexa 647 557783 BD Pharmingen
Cell Population Stainings
T (thymus) Cells CD3+ CD45+
Granulocytes CD66b+ CD45+
Eosinophils CD66b+ CD125+ SSC (side scatter) high CD45+
Neutrophils CD66b+ CD125- SSC high CD45+
Basophils CD66b+ CD125- SSC low CD45+
Monocytes CD14 low and high CD45+
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Figure 42.  Representative granulocyte gating for cell population-associated FAP expression, illustrates 
enhanced FAP expression in granulocytes.  Granulocytes are first gated by CD66b expression and side 
scatter in peripheral blood (A) and thrombi specimens (B). C. Granulocyte-specific FAP expression is 
quantified as the mean fluorescent intensity from the histogram generated by F19 (black) and a matching 
isotype control antibody (grey) stainings in both peripheral blood (C) and thrombi (D). E. The increase of 
granulocyte-specific FAP expression is shown by the change of mean fluorescent intensity between 
peripheral blood (grey) and thrombi (black).  
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Figure 43.  Representative granulocyte subset gating for cell sub-population-associated FAP expression 
illustrates enhanced FAP expression in thrombus basophils.  Granulocytes pre-gated by CD66b/side 
scatter, are further gated into granulocyte subsets by CD125 and side scatter in peripheral blood (A) and 
thrombus specimens (B). Basophil-specific FAP expression is quantified as the mean fluorescent intensity 
from the histogram generated by FAP-specific staining (black) and a matching isotype control antibody 
(grey) for both peripheral blood (C) and thrombi (D). E. The increase of basophil-specific FAP is shown by 
the change of mean fluorescent intensity of peripheral blood (grey) vs. thrombi (black).  
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Figure 44.  Eosinophil-associated FAP expression is enhanced in peripheral blood (PB) vs. coronary (TH) 
thrombi. FAP expression in eosinophils pre-gated by side scatter and CD125 (Figure 43),  is quantified as the 
mean fluorescent intensity from the histogram generated by FAP-specific antibody F19 (black) and a 
matching isotype control antibody (grey) for both peripheral blood (A) and thrombi (B). C. The increase of 
eosinophil-specific FAP expression is shown by the change of mean fluorescent intensity of the F19 
histogram for peripheral blood (grey) and thrombi (black).  
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Figure 45.  Neutrophil-associated FAP expression is enhanced in peripheral blood (PB) vs. coronary thrombi 
(TH).  A-B. FAP expression in neutrophils pre-gated by side scatter and CD125 (Figure 43)  is quantified as the 
change in mean fluorescent intensity generated by FAP-specific F19 (black) and a matching isotype control 
antibody (grey) for both peripheral blood (A) and coronary thrombi (B). C.  The increase of neutrophil-specific 
FAP binding is shown by the change of mean fluorescent intensity for F19 binding in peripheral blood (grey) 
and coronary thrombi (black).  
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Figure 46.  Representative monocyte gating for cell population-associated FAP protein expression.  
Monocytes are first gated by CD45 expression and side scatter in peripheral blood (A) and thrombi 
specimens (B) and then by CD45 expression and size (Forward Scatter; C-D).   
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Figure 47.  Monocyte-associated FAP expression is unchanged in peripheral blood (PB) vs. coronary 
thrombi (TH). FAP expression in monocytes  is quantified as the mean fluorescent intensity from the 
histogram of F19 binding (black) and a matching isotype control antibody (grey) for both peripheral 
blood (A) and thrombi (B).  C. The monocyte-specific FAP expression in thrombi is shown by the change 
of mean fluorescent intensity of F19 staining in peripheral blood (grey) vs. thrombi (black).  
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Figure 48.  Lymphocyte-associated FAP expression is unchanged in peripheral blood (PB) 
vs. coronary thrombi (TH). FAP binding in lymphocytes pre-gated by side scatter (SSC-H) 
and CD45 in peripheral blood and matching thrombus  is quantified as the mean fluorescent 
intensity from the histogram generated by F19 (black) and a matching isotype control 
antibody (grey) for both peripheral blood (A) and thrombi (B).  The increase of lymphocyte-
specific FAP expression is shown by the change of mean fluorescent intensity between FAP-
specific F19 binding (black) and an isotype control antibody (grey) for peripheral blood (C) 
and thrombi (D).  
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Figure 49.  FAP is enhanced in human coronary thrombi vs. peripheral blood in STEMI patients.  A. Representative immunohistological 
stainings illustrate enhanced FAP in coronary thrombi vs. peripheral blood. B.  FAP mRNA is enhanced in coronary thrombi (Thr) vs. peripheral 
blood leukocytes (PBL).  (* = p < 0.05, n=6)  
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4.4 RESULTS 
 
4.4.1  FAP EXPRESSION IS ENHANCED IN HUMAN CORONARY THROMBI 
 
Immunohistochemical stainings for FAP in adjacent paraffin-embedded sections reveal enhanced FAP 
expression in human coronary thrombi vs. peripheral blood (Figure 49A). Positive staining for FAP is 
virtually absent in peripheral blood, and FAP mRNA is increased in coronary thrombi by RT-PCR analysis 
(Figure 49B). 
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Figure 50. FAP expression in human coronary thrombi colocalizes with granulocytes, but 
not with monocytes/macrophages or T-cells. Overlays of confocal images of FAP (red) and 
DAPI (blue) with cell-specific stainings of CD66b, CD14, and CD3 (green) in representative 
cryosections of human coronary thrombi illustrate FAP colocalization (arrows) with 
granulocytes (bar=5 µm).  
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4.4.2  FAP IS EXPRESSED BY GRANULOCYTES IN HUMAN CORONARY THROMBI 
 
To characterize FAP-expressing cell types in human thrombi, we performed immunofluorescent co-stainings of 
FAP in monocytes/macrophages (identified as CD14-positive cells), granulocytes (CD68-positive cells), and T-
Lymphocytes (CD3-positive cells). Confocal image analyses revealed FAP expression by granulocytes, but not by 
macrophages or endothelial cells (Figure 50). 
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Figure 51. FAP expression is enhanced in thrombus neutrophils and 
granulocytes in STEMI patients suffering myocardial infarction. FAP 
expression is quantified in peripheral blood (PB) vs. coronary thrombus (TH) 
derived monocytes (A), T-Cells (B), and granulocytes (C), eosinophils (D), 
neutrophils (E), and basophils (F).   FAP is enhanced in thrombus all 
granulocytes and in the neutrophil sub-population.  
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4.4.3  FAP EXPRESSION IS INCREASED IN CORONARY THROMBUS NEUTROPHILS  
 
We used flow cytometry to quantify FAP expression in human peripheral blood vs. thrombus 
leukocyte cell populations including; monocytes, T-Cells, granulocytes, neutrophils, eosinophils, and 
basophils. Quantitative analyses revealed enhanced FAP expression in thrombus granulocytes and 
neutrophils, but in none of the other analyzed cell populations (Figure 51). 
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4.4.4  NEUTROPHIL-SPECIFIC FAP EXPRESSION IS ENHANCED IN STEMI BUT NOT PAOD 
PATIENTS 
 
To access whether neutrophil-specific FAP expression associates with acute atherothrombosis, we 
used flow cytometry to quantify FAP expression in peripheral blood and occluding thrombi from patients 
suffering from STEMI (coronary artery thrombi) and PAOD (femoral artery thrombi).  Acutely formed 
coronary thrombi showed increased expression of FAP compared to chronic peripheral artery derived 
thrombi (Figure 52).   
 
 
 
 
 
 
 
 
 
 
 
Figure 52. Neutrophil FAP expression is 
enhanced in acute, but not chronic 
atherothrombosis. Neutrophil FAP 
expression is enhanced in peripheral 
blood (white bar) and occluding thrombi 
(grey bar) from patients with myocardial 
infarction (MI, n=9) compared to patients 
with peripheral artery occlusive disease 
(PAOD, n=5).  
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4.4.5  FAP IS EXPRESSED IN THE ENDOTHELIUM OF HUMAN CORONARY THIN-CAP 
FIBROATHEROMATA 
 
In order to determine FAP expression in the endothelium of human coronary fibrous caps, we stained 
H&E stainings in rupture-prone human coronary arteries obtained from patients that died after 
myocardial infarction and healthy internal mammary arteries as control. Immunohistological stainings 
revealed FAP expression in the fibroatheromata endothelium (Figure 53). 
  
Figure 53. FAP is expressed in the endothelium of human thin-cap coronary 
fibroatheromata. H&E staining shows an internal mammary artery and a thin-cap 
coronary fibroatheromata (L=lumen, FC=fibrous cap, NC=necrotric core; bar=1mm).  
FAP and CD31 immunohistochemistry (bar = 50µm) shows FAP expression in the 
endothelium (arrows). Dotted boxes indicate regions of interest in adjacent sections 
at high magnification, and stainings with isotype control antibodies are shown.  
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4.4.6  FAP ACCELERATES HUMAN BLOOD COAGULATION AND INCREASES CLOT THICKNESS 
 
To determine the role of FAP in accelerated blood coagulation and clot thickness, healthy human 
blood was treated with 1.75µg/mL recombinant FAP with the optimal dosage (1.75µg/mL) for the 
optimal incubation time (5hr).  FAP was found to accelerate blood clotting time and clot formation 
compared to a vehicle control, time while increasing the alpha angle and maximum clot firmness by 
NATEM (Figure 54). 
 
 
  
Figure 54. FAP accelerates blood clotting time and clot formation time while increasing the 
alpha angle and maximum clot firmness by NATEM analysis. Absolute clotting time and clot 
formation time decreased in 5/6 probands, alpha angle increased in 5/6 patients, and maximum 
clot thickness increased in 4/6 probands when conditioned with 1.75ug/mL of FAP at 5hr 
incubation compared to vehicle treated control.  Averages are shown indicated by the black line.   
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4.4.7  FAP PROMOTES BLOOD COAGUATION IN A DOSE AND TIME-DEPENDANT MANNER 
 
To determine a causal role of FAP in thrombus formation, the dose and time-dependant effects of 
recombinant human FAP on healthy human blood coagulation was assessed ex-vivo by NATEM analysis.  
The effect of FAP was both time and dose dependant (Figure 55). 
 
 
 
 
 
 
 
  
 
Figure 55. FAP promotes blood coagulation in a time and dose-dependent manner ex-vivo by NATEM.  
Blood from healthy probands (n=6) was conditioned with recombinant human FAP at 0.175 (green), 1.75 
(grey), and 3.5 µg/mL (black) for 0, 2.5, 5hr incubation.  Average values and standard deviations compared 
to unconditioned controls 0µg/mL are shown (*, p<0.05 ; **, p<0.01, Student’s T-test).  
 
-60
-50
-40
-30
-20
-10
0
10
0 2.5 5
%
 o
f V
eh
ic
le
 (0
 u
g/
m
L)
 c
on
tr
ol
Incubation time (hr)
Clotting Time
0.175 µg/mL
1.75 µg/mL
3.5 µg/mL
-10
-5
0
5
10
15
20
25
0 2.5 5
%
 o
f V
eh
ic
le
 (0
ug
/m
L)
 c
on
tr
ol
Incubation time (hr)
Maximum Clot Firmness
0.175 µg/mL
1.75 µg/mL
3.5 µg/mL
-20
-10
0
10
20
30
40
0 2.5 5
%
 o
f V
eh
ic
le
 (0
ug
/m
L)
 c
on
tr
ol
Incubation time (hr)
Alpha Angle
0.175 µg/mL
1.75 µg/mL
3.5 µg/mL
-80
-60
-40
-20
0
20
40
0 2.5 5
%
 o
f V
eh
ic
le
 (0
ug
/m
L)
 c
on
tr
ol
Incubation time (hr)
Clot Formation Time
0.175 µg/mL
1.75 µg/mL
3.5 µg/mL
*
**
*
*
*
Chapter 4  81 
4.5 DISCUSSION 
 
Atherothrombosis is caused by plaque disruption via fibrous cap rupture and also by superficial 
erosion of the intima.  The severity of the thrombotic complications is governed by both the thrombotic 
components of the disrupted plaque, and also the systemic thrombogenic state of the blood.    
This study links the constitutively active serine protease FAP to coronary atherothrombosis and 
provides evidence that: (1) FAP is enhanced in occlusive coronary thrombi, (2) FAP is expressed by 
neutrophils during acute thrombus formation, (3) FAP is expressed in the endothelium of thin-cap 
fibroatheromata, (4) FAP accelerates blood coagulation and clot thickness. 
Numerous studies implicate elevated systemic levels of plaque-derived prothrombogenic factors such 
as tissue factor, von Willebrand factor, and factor  VIII in atherothrombosis.10, 11  However, these 
hallmark coagulation factors play no known role in plaque destabilization and fibrous cap rupture.  FAP 
expression was particularly enhanced in the endothelium of thin-cap coronary fibroatheromata and in 
coronary thrombus neutrophils. Moreover, FAP was shown to accelerate blood coagulation.  Taken 
together, our findings provide evidence that FAP is the first known collagenase contributing to both 
plaque destabilization and atherothrombosis.  These observations underline the potential clinical 
relevance of FAP and a diagnostic and/or therapeutic target in patients with advanced atherosclerotic 
plaques.    
Neutrophil levels have also been shown to associate with future cardiovascular events.12  However, 
the causal role of neutrophils in atherothrombosis remains largely conjectural. In rupture-prone carotid 
plaque, neutrophils have been shown to release destabilizing proteases, and associate with intraplaque 
hemorrhage.13   Recent work by Massberg et al also identifies a role of neutrophils in thrombosis via 
releasing neutrophil serine proteases, which degrade the anticoagulant tissue-factor pathway inhibitor 
(TFPI), thereby enhancing coagulation and thrombus formation.14  Our findings show further 
contribution of neutrophils to atherothrombosis via expression of FAP, and thereby adds to this growing 
body of evidence which supports the notion of neutrophil involvement in atherothrombosis.  
We also found constitutive FAP expression in endothelial cells of thin-cap fibroatheromata. 
Endothelial activation dysfunction plays a central role in atherothrombosis.15 Activated endothelial cells 
express fibrous cap-degrading collagenases, and have also been shown to act in concert with fibrous 
cap-degrading smooth muscle cells.16-18 FAP expression in the endothelium of thin capped 
fibroatheromata may indicate a role of FAP in superficial intimal erosion.  Moreover FAP expression in 
the endothelium may indicate its long-term interaction with blood, which could promote a chronic 
hyperthrombogenic state. 
Taken together, we found that FAP expression is enhanced in human coronary thrombi, and in the 
endothelium of thin-cap coronary fibroatheromata.  FAP was also found to and accelerate blood 
coagulation.  Thus, FAP expression in thin-cap coronary plaques and coronary thrombi renders it an 
attractive diagnostic target for further investigation in patients with ACS.   Along this line, the ability of 
FAP to accelerate blood coagulation may also draw attention to its potential as a therapeutic target.  We 
now aim to investigate the effect of FAP in atherothrombosis in vivo via genetic and pharmacological 
modulation, and to also investigate the mechanism of FAP induction in both endothelial cells and 
neutrophils.  On a clinical level, associations of soluble FAP levels to inflammatory diseases such as 
rheumatoid arthritis and chronic liver disease may shed light on its potential clinical use as a diagnostic 
biomarker.  
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5.1 THE ROLE OF FAP IN INFLAMMATORY DISEASE 
 
While atherosclerosis is a chronic disease that begins early in life, late-stage vulnerable plaques are 
the most clinically relevant.  Indeed many individuals live long lives with significant plaque burden, and 
never experience symptoms. Conversely, other individuals with comparatively little plaque burden may 
succumb to cardiovascular events at a young age due to a single vulnerable plaque disruption.  
Therefore a mechanistic understanding of the factors involved in plaque vulnerability and 
atherothrombosis remain of high clinical importance.  
Nature teaches us that atherosclerosis and vulnerable plaque rupture parallels the pathophysiology of 
other inflammatory diseases such as chronic liver disease and rheumatoid arthritis.  Therefore, in 
formulating the hypotheses presented in this thesis, we closely observed similar pathways in other 
inflammatory diseases and often found the congruent mechanisms of action.  Indeed the finding of 
macrophage-induced FAP expression is a key underpinning of these findings.  Specifically we found that 
macrophage-derived TNF-α induced FAP expression in vascular smooth muscle cells.  This is the first 
published mechanism of FAP expression in a mesenchymal cell population by inflammatory stimuli.  
Given FAP’s collagenase and prothrombotic activities, these findings may be extrapolated to other FAP 
associated inflammatory diseases (i.e. rheumatoid arthritis, chronic liver disease, and tumor formation) 
and underline the therapeutic potential of anti-FAP therapies.  
A common pathological mechanism of vulnerable plaque rupture, tumour formation, and 
atherothrombosis is angiogensis.  In vulnerable plaques, angiogenesis leads to vasa vasorum formation, 
which in turn directs intraplaque hemorrhage and lesion complication.1  Neovacularization in 
rheumatoid arthritis provides nutrients for pathological tissue formation which contributes to disease 
progression.   FAP has been shown to work in concert with CD26 to promote angiogenesis, via invading 
endothelial cells. 2, 3 In our studies, we found that thin-cap human coronary atheromata endothelial cells 
also express FAP.  This finding combined with the known role of FAP in neovascularization, may indicate 
a potential contributory role of FAP in vasa vasorum formation and highlight the potential of anti-FAP 
strategies in preventing pathogenic angiogenesis.   
Hyperthrombogenic blood increases patient vulnerability to cardiovascular events including 
myocardial infarction, peripheral artery occlusive disease, and stroke.4  We found enhanced FAP in 
rupture-prone atherosclerotic plaque and in occluding coronary thrombi, and also identified its causal 
role in accelerated blood coagulation.  Given the know presence of FAP in other inflammatory diseases 
(i.e. rheumatoid arthritis and chronic inflammatory liver disease), it is plausible the FAP also spills-over 
into the blood and may play a role in accelerated blood coagulation of these diseases as well.  
Interestingly patients with rheumatoid arthritis are at an increased risk of atherothrombotic events.5  
Therefore, it is plausible that FAP may contribute to this link.  
 
5.4 FUTURE STUDIES - OUTLOOK 
 
While this work associated FAP expression to plaque progression and atherothrombosis, evidence as 
to the causal role of FAP in-vivo is still missing.  Further in-vitro studies will also be needed to address 
the mechanism of FAP induction in endothelial cells and may also shed light on the role of FAP in other 
inflammatory diseases.   To identify a clinical application of the work presented in this thesis, the 
potential of FAP as a diagnostic biomarker in patients with acute coronary syndromes should be 
addressed.  Moreover the effect of FAP inhibiting agents on blood coagulation ex-vivo should be 
identified. 
To identify the causal for of FAP in atherogenesis, we have performed preliminary studies in 
atherosclerotic Apolipoprotein E deficient mice (ApoE-/-), to determine if this model is suitable for the 
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Figure 56.  ApoE-/- mice on high cholesterol diet express FAP in atherosclerotic 
plaques. A.  H&E staining shows aortic roots from healthy wildtype and atherosclerotic 
ApoE-/- mice (scale=300µm).  Regions of interest indicated by the black boxes are shown 
at high magnification (inlays, scale=50µm).  Adjacent staining reveal FAP expression (red) 
in ApoE-/-  plaques, but not in healthy wild-type arteries. Sections are counterstained in 
DAPI (blue)   B. FAP expression is quantitatively greater in ApoE-/- mice (n=5) compared 
to WT controls (n=4).   
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study of FAP in-vivo.  It was found 
that the ApoE-/- mouse on a high 
cholesterol diet indeed express FAP 
in atherosclerotic plaque (Figure 56).  
Therefore, future experiments may 
seek to generate an ApoE-/-FAP-/- 
mouse to determine the role of FAP 
on atherogenesis and thrombosis in-
vivo.      
To determine whether FAP can be 
used as a therapeutic target against 
atherothrombosis in-vivo remains to 
be seen.  We intend to approach this 
question by first testing the effect of 
FAP-specific inhibiting agents on 
coagulation of blood from human 
patients ex-vivo.  Specifically, blood 
will be drawn from patients with 
acute coronary syndromes  and 
treated with FAP-inhibiting agents to 
assess their effect on blood 
coagulation.    
 
 
5.2 POTENTIAL OF FAP AS A DIAGNOSTIC TARGET 
 
While we found that FAP associates with vulnerable plaque rupture and atherothrombosis, its 
potential as a target for clinical use has not been assessed.  As FAP is expressed in the endothelium of 
thin-cap coronary fibroatheromata and neutrophils of occluding coronary thrombi, it is plausible that 
soluble forms of FAP may indeed spill over into the circulation.  While circulating FAP has been detected 
in human blood (identified as Anti-plasmin cleaving enzyme) its value as a predictive marker of 
cardiovascular events has not been assessed on any level.6  We found that FAP was specifically 
enhanced in the acute coronary thrombi, but not in chronic peripheral artery thrombi.  Therefore, FAP 
levels may specifically associate to the risk of acute, but not slow-forming chronic events.    Moreover, 
the direct causal role of FAP in accelerated blood coagulation supports the notion of its role in acute 
thrombus formation.  However, it is important to note that FAP is not known to play a direct role in 
blood coagulation, but rather acts via the activation α2-antiplasmin which in turn inhibits plasmin 
mediated fibrinolysis.  Therefore, antiplasmin may have yet better potential as a diagnostic biomarker 
than FAP. 
Expression of FAP in the endothelium of thin-cap coronary fibroatheromata may attract interest in FAP 
directed molecular imaging.  Currently there is an unmet clinical need to identify rupture prone 
atherosclerotic plaques.  FAP-directed molecular imaging may theoretically employ a labeled FAP-
specific agent which, when introduced into the blood, would bind FAP on the superficial surface of the 
plaque.  In cases of atherothrombosis due to coronary fibrous cap rupture, it may be plausible that the 
imaging agent binds directly to the endothelium in the vulnerable fibrous cap.  Even in cases of 
superficial intimal erosion, where an intact endothelium is not present, our data suggests that FAP is 
highly expressed in the intima.  Therefore, it is plausible that FAP directed molecular imaging may hold 
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future potential in diagnostic strategies. However, the feasibility of this approach has not yet been 
verified on any level. 
  
5.3 POTENTIAL OF FAP AS A THERAPEUTIC TARGET 
 
Given the role FAP in fibrous cap collagen degradation presented in this thesis, inhibition of FAP 
activity may draw interest as a therapeutic strategy to prevent plaque rupture.  Moreover, the 
contribution of FAP in accelerated blood coagulation may present future therapeutic options.  Indeed 
FAP has been pursued in the past as a therapeutic target in tumor formation, via two different 
approaches.   
First, in antibody based imaging studies, the FAP-specific antibody F19 was found to specifically bind 
tumors in patients.  However, F19 does not inhibit FAP. While F19 was well tolerated, it showed no 
efficacy in a phase II trial for metastatic colorectal cancer.7  However, more recently it has been reported 
that an F19 conjugated to maytansinoid, a cytotoxic drug, could inhibit tumor growth and was well 
tolerated.8  Moreover, another group has reported that antibodies which inhibit the proteolytic activity 
of FAP slowed tumor growth in a xenograft model.9  However, whether these approaches can be 
directed toward atherosclerosis remains to be seen.   
Several groups have also attempted to inhibit FAP’s enzymatic activity using inhibiting small chemical 
molecules.  Val-boro-Pro (PT-100; Talabostat) demonstrates potential to attenuate tumor growth in a 
variety of tumor mouse models.  While this drug was well tolerated and effective in preliminary trial, it 
failed to pass phase III clinical trials due to inefficacy in treating lung cancer.  Moreover the use of  Val-
boro-Pro to inhibit FAP’s enzymatic activity is not specific, as it also inhibits CD26 and DPP7, which may 
lead to undesired side effects and safety concerns.    
Taken together, FAP does show early potential as a therapeutic target against tumor formation.  
However,   the potential of FAP-inhibition in vulnerable coronary plaque rupture and atherothrombosis 
remains to be seen.  Further pre-clinical trials in atherosclerotic animal models will be useful in 
identifying the therapeutic benefit of FAP-inhibition.   
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6.1 IMAGE ANALYSIS SOFTWARE CODE – BACKGROUND SUBTRACTION 
 
The below image analysis Matlab 7.10.0 code was used to perform isotype control and background signal 
subtraction, while calculating representative histograms. 
 
clear  
threshold = 0; 
% Image input - Cy3 & Cy5 VAIRABLE ARE ESPECIALLY FOR Cy3 AND Cy5 
% RESPECTIVELY (FOR PROPER COLOCALIZATION COEFFICIENT READOUT) 
  
%Import Images 
  
    % Sample Images  
    Cy3 = imread('Sample_Image_Cy3.tif'); %import picture - green channel = 
Cy3(:,:,2)% 
    Cy5 = imread('Sample_Image_Cy5.tif'); %import picture - red channel = 
Cy5(:,:,1)% 
  
    % Isotype Images (image from the antibody isotype control) 
    iCy3 = imread('Isotype_Image_Cy3.tif'); %import isotype control picture - 
green channel = Cy3(:,:,2)% 
    iCy5 = imread('Isotype_Image_Cy5.tif'); %import isotype control picture - 
red channel = Cy5(:,:,1)% 
     
    % Background Images (image from different plane - average is 200 microns 
under the sample, in the glass slide) 
    bCy3 = imread('Background_Image_Cy3.tif'); %import background picture - 
green channel = Cy3(:,:,2)% 
    bCy5 = imread('Background_Image_Cy5.tif'); %import background picture - 
red channel = Cy5(:,:,1)% 
      
%Background Thresholds   
     
    % Thresholds for the isotype control images 
    i_backlimit = .95;  % background Cy3 percent limit 
    i_backlimitT = .05; % background Cy5 percent limit (percentage of the 
pixels from the background image should be removed from the sample image) 
     
    % Thresholds for the background image                 
    backlimit = .95;  % background Cy3 percent limit 
    backlimitT = .05; % background Cy5 percent limit (percentage of the 
pixels from the background image should be removed from the sample image) 
  
% Create blank Scatter plot Matrix (255x255, all zeros) 
  
SP = zeros(256,256,3); 
NSP = zeros(256,256,3); 
  
% Green Channel (standard is Cy3) 
  
    % Sample Image 
    X = size(Cy3);  
    A = Cy3; 
    A(:,:,1) = []; 
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    A(:,:,2) = []; 
    Max3 = double(max(max(A))); % Maximum Cy3 value for the normalized 
scattergram 
  
    % Aimage for the unadjusted image output in the final figure 
    Aimage = A; 
     
    % Background Image 
    bX = size(bCy3);  
    bA = bCy3; 
    bA(:,:,1) = []; 
    bA(:,:,2) = []; 
  
    % Isotype Image 
    iX = size(iCy3);  
    iA = iCy3; 
    iA(:,:,1) = []; 
    iA(:,:,2) = []; 
     
    % Define variables for the first channel 
    Ncol = X(2); 
    col = 1; 
    Nrow = X(1); 
    row = 1; 
     
    % Calculate average pixel for the FIRST Channel 
     
    B = sum(A); 
    C = sum(B); 
    Cy3_Cumulative_Before = C 
    AV_before = C /(Ncol*Nrow); 
    Cy3_Average_Before = AV_before      
  
% Red Channel (standard is Cy5) 
  
    %Sample Image 
    XT = size(Cy5);  
    AT = Cy5; 
    AT(:,:,2) = []; 
    AT(:,:,2) = []; 
    Max5 = double(max(max(AT))); % Maximum Cy5 value for the normalized 
scattergram 
  
    % ATimage for the unadjusted image output in the final figure 
    ATimage = AT; 
   
    % Background Image 
    bXT = size(bCy5);  
    bAT = bCy5; 
    bAT(:,:,2) = []; 
    bAT(:,:,2) = []; 
     
    % Isotype Image 
    iXT = size(iCy5);  
    iAT = iCy5; 
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    iAT(:,:,2) = []; 
    iAT(:,:,2) = []; 
  
    %  Define variables for the SECOND channel 
  
    NcolT = XT(2); 
    colT = 1; 
    NrowT = XT(1); 
    rowT = 1; 
      
     % Calculate the average for the SECOND Channel  
      
     BT = sum(AT); 
     CT = sum(BT); 
     Cy5_Cumulative_before = CT; 
     AV_beforeT = CT/(Ncol*Nrow); 
     Cy5_Average_Before= AV_beforeT;  
  
% Background calculation to identify threshold 
      
     % Cy3 calculation 
                                     
            % Background Image Subtraction 
                bA = double(bA); 
                n_vector = reshape(bA.',[],1); 
                n_vector_d = double(n_vector); 
                n_b_HIST = hist(n_vector_d, 255); 
                Sum_shar = sum(n_b_HIST);  % sum of all pixels 
                w = Sum_shar * backlimit; % number of pixels above backlimit  
                rest = Sum_shar - w; % number of pixels below the 5% 
threshold 
                i = 1; % background loop index and threshold value (after the 
loop is ran) 
                y = 0; % cumulation of pixels below threshold 
                while y < w; 
                    y = y + n_b_HIST(i); 
                    i=i+1; 
                end 
                threshold = i-1; 
                        
            % Isotype Control Image Subraction             
                iA = double(iA); 
                n_vector = reshape(iA.',[],1); 
                n_vector_d = double(n_vector); 
                n_b_HIST = hist(n_vector_d, 255); 
                Sum_shar = sum(n_b_HIST);  % sum of all pixels 
                w = Sum_shar * backlimit; % number of pixels above backlimit  
                rest = Sum_shar - w; % number of pixels below the 5% 
threshold 
                i = 1; % background loop index and threshold value (after the 
loop is ran) 
                y = 0; % cumulation of pixels below threshold 
                while y < w; 
                    y = y + n_b_HIST(i); 
                    i=i+1; 
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                end 
                i_threshold = i-1; 
  
     % Cy5 calculation 
             
            % Background Control Image Threshold Calculation                
  
                bAT = double(bAT); 
                nT_vector = reshape(bAT.',[],1); 
                nT_vector_d = double(nT_vector); 
                Sum_nT_vector_d = sum(nT_vector_d); % Sum_nT_vector_d = Sum 
of all pixel intensities 
                Sum_nT_vector_d_limit = Sum_nT_vector_d * backlimitT; % 
Sum_nT_vector_d_limit = value of pixels below threshold  
                nT_b_HIST = hist(nT_vector_d, 255); 
                Sum_nT_b_HIST = sum(nT_b_HIST); 
                HIST_Limit = Sum_nT_b_HIST * backlimitT; 
                iT = 1; % background loop index (and threshold value - after 
the loop is ran) 
                yT = 0; % accumulation of pixels below backlimit 
                % find the intensity when the threshold exists 
                while yT < HIST_Limit; 
                    % yT = current value leading up to Sum_sharT (Sum_sharT = 
the sum of pixels below the threshold), frequency = (nT_b_HIST(iT)),  
intensity = (iT)  
                    yT = yT + (nT_b_HIST(iT)); 
                    iT=iT+1; 
                end 
                                 
                thresholdT = iT-1; 
                %Cy5_Background_Threshold = the intensity below which 
                %sample pixel will be excluded. 
                 
                Cy5_Background_Threshold = thresholdT  
                Cy5_Background_Threshold_bin = round(thresholdT/5);  
                               
  
            % Isotype Control Image Threshold Calculation        
                 
                iAT = double(iAT); 
                nT_vector = reshape(iAT.',[],1); 
                nT_vector_d = double(nT_vector); 
                Sum_nT_vector_d = sum(nT_vector_d); % Sum_nT_vector_d = Sum 
of all pixel intensities 
                Sum_nT_vector_d_limit = Sum_nT_vector_d * i_backlimitT; % 
Sum_nT_vector_d_limit = value of pixels below threshold  
                nT_b_HIST = hist(nT_vector_d, 255); 
                Sum_nT_b_HIST = sum(nT_b_HIST); 
                HIST_Limit = Sum_nT_b_HIST * i_backlimitT; 
                iT = 1; % background loop index (and threshold value - after 
the loop is ran) 
                yT = 0; % accumulation of pixels below backlimit 
                % find the intensity when the threshold exists 
                while yT < HIST_Limit; 
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                    % yT = current value leading up to Sum_sharT (Sum_sharT = 
the sum of pixels below the threshold), frequency = (nT_b_HIST(iT)),  
intensity = (iT)  
                    HIST_Limit; 
                    yT = yT + (nT_b_HIST(iT)); 
                    iT=iT+1; 
                end 
                 
                 
                i_thresholdT = iT-1; 
                %Cy5_Isotype_Threshold = the intensity below which 
                %sample pixel will be excluded. 
                 
                Cy5_Isotype_Threshold = i_thresholdT 
                Cy5_Isotype_Threshold_bin = round(i_thresholdT/5); 
  
                % define arbitrary variable values for the while loop 
  
                p = 0; 
                q = 0; 
                tdif = 0; 
                dif = 0; 
                tavg = 0; 
                tavgt = 0;  
                tclc = 0; 
                gel = 0; 
                counted = 0; 
  
  
                    % Validates that images are of the same dimensions  
  
                    if (Ncol ~= NcolT); 
                        error('images of different sizes') 
                    end 
  
                    if (Nrow ~= NrowT); 
                        error('images of different sizes') 
                    end 
                     
                     
% Generate a histogram of intensities from the Cy5 image 
  
%Sample Image 
    Cy5_vector = reshape(AT.',[],1); 
    Cy5_vector_d = double(Cy5_vector); 
    Cy5_HIST = hist(Cy5_vector_d, 100); 
  
%Background Image  
    Cy5_b_vector = reshape(bAT.',[],1); 
    Cy5_b_vector_d = double(Cy5_b_vector); 
    Cy5_b_HIST = hist(Cy5_b_vector_d, 100); 
  
%Isotype control Image  
    Cy5_i_vector = reshape(iAT.',[],1); 
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    Cy5_i_vector_d = double(Cy5_i_vector); 
    Cy5_i_HIST = hist(Cy5_i_vector_d, 100); 
  
% Generate custom histograms of intensities from the Cy5 image for plotting 
with the bar function     
  
% Sample Image Histogram Calculations 
    % Reshape the image into a vector        
        Cy5_Image_vector = reshape(AT.',[],1); 
        Cy5_Image_vector = double(Cy5_Image_vector); 
    % Set the histogram vector to 255 zeros 
        Cy5_Sample_Histogram_Vector = zeros([1 51]); 
    % Bin the pixel intensity values into the histogram vector     
        i=1; 
        % Loop through the image vector 
        while i <= length(Cy5_Image_vector) 
            t=1; 
            y=0; 
            % Place the pixel values into the histogram vector 
            while y < 1 
                bins = 5*t; 
                if Cy5_Image_vector(i) <= bins 
                    Cy5_Sample_Histogram_Vector(t) = 
Cy5_Sample_Histogram_Vector(t) + 1; 
                    y = 2; 
                end 
            t=t+1; 
            end 
                         
            i=i+1; 
        end 
         
        Cy5_Sample_Histogram_Vector_new = Cy5_Sample_Histogram_Vector; 
         
% Background Image Histogram Calculations 
    % Reshape the image into a vector        
        Cy5_Background_vector = reshape(bAT.',[],1); 
        Cy5_Background_vector = double(Cy5_Background_vector); 
    % Set the histogram vector to 255 zeros 
        Cy5_Background_Histogram_Vector = zeros([1 51]); 
    % Bin the pixel intensity values into the histogram vector     
        i=1; 
        % Loop through the Background vector 
        while i <= length(Cy5_Background_vector) 
            t=1; 
            y=0; 
            % Place the pixel values into the histogram vector 
            while y < 1 
                bins = 5*t; 
                if Cy5_Background_vector(i) <= bins 
                    Cy5_Background_Histogram_Vector(t) = 
Cy5_Background_Histogram_Vector(t) + 1; 
                    y = 2; 
                end 
            t=t+1; 
            end 
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            i=i+1; 
        end 
         
% Bin the background threshold into the original         
        Cy5_Background_Threshold_bin = round(Cy5_Background_Threshold / 5) ; 
        Cy5_Background_Histogram_Vector_new = 
Cy5_Background_Histogram_Vector; 
  
% In Cy5_S_minus_B, set all values below the Cy5_Background_Threshold equal 
to zero.  
        Cy5_S_minus_B = Cy5_Sample_Histogram_Vector; 
        %Loop through Cy5_S_minus_B_before, setting everything below 
Cy5_Background_Threshold equal to zero.   
            i=1; 
            Cy5_Background_Threshold_Bin = ((Cy5_Background_Threshold/5)-1); 
            while i < Cy5_Background_Threshold_Bin 
                    Cy5_S_minus_B(i) = 0; 
                  i=i+1; 
            end 
          
             
% Isotype Image Histogram Calculations 
    % Reshape the image into a vector        
        Cy5_Isotype_vector = reshape(iAT.',[],1); 
        Cy5_Isotype_vector = double(Cy5_Isotype_vector); 
    % Set the histogram vector to 255 zeros 
        Cy5_Isotype_Histogram_Vector = zeros([1 51]); 
    % Bin the pixel intensity values into the histogram vector     
        i=1; 
        % Loop through the Isotype vector 
        while i <= length(Cy5_Isotype_vector) 
            t=1;     
            y=0; 
            % Place the pixel values into the histogram vector 
            while y < 1 
                bins = 5*t; 
                if Cy5_Isotype_vector(i) <= bins 
                    Cy5_Isotype_Histogram_Vector(t) = 
Cy5_Isotype_Histogram_Vector(t) + 1; 
                    y = 2; 
                end 
            t=t+1; 
            end 
                         
            i=i+1; 
        end 
         
% Bin the Isotype threshold into the original         
        Cy5_Isotype_Threshold_bin = round(Cy5_Isotype_Threshold / 5) ; 
        Cy5_Isotype_Histogram_Vector_new = Cy5_Isotype_Histogram_Vector; 
         
         
         
       % Cy5_Isotype_Threshold_bin = Cy5_Isotype_Threshold_bin + 3; 
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% In Cy5_S_minus_I, set all values below the Cy5_Isotype_Threshold equal to 
zero.  
        Cy5_S_minus_I = Cy5_S_minus_B; 
        %Loop through Cy5_S_minus_I_before, setting everything below 
Cy5_Isotype_Threshold equal to zero.   
            i=1; 
            %Cy5_Isotype_Threshold_Bin = Cy5_Isotype_Threshold_Bin-1; 
            while i < Cy5_Isotype_Threshold_bin 
                    Cy5_S_minus_I(i) = 0; 
                    i=i+1; 
            end         
         
  
             
% BACKGROUND control sub-threshold pixel removal 
  
col = 1; 
  
    while col <  Ncol 
       row = 1; 
       while row < Nrow 
  
    % Change every value that is below BACKGROUND threshold to zero 
  
    % Cy3  
        % Remove BACKGROUND AND ISOTYPE Control Image Threshold 
            if A(row, col) < threshold 
                A(row, col) = 0; 
            end 
  
    % Cy5    
       % Remove BACKGROUND AND ISOTYPE Control Image Threshold 
            if AT(row, col) < thresholdT 
                AT(row, col) = 0; 
            end  
  
       row = row +1; 
      end 
       col = col +1; 
    end             
             
% Set the Sample - Background subtrated matix to report as an image 
  
    %Cy3 
        Cy3_S_min_B_grey = mat2gray(A); 
    %Cy5 
        Cy5_S_min_B_grey = mat2gray(AT); 
  
% Calculate the Background subtracted images 
         
    %Cy3 
        Cy3_S_min_B = reshape(A.',[],1); 
Chapter 6  99 
        Cy3_S_min_B = double(Cy3_S_min_B); 
        Cy3_S_min_B_HIST = hist(Cy3_S_min_B, 255); 
        %Remove the values from 1 to 3 intensity  
        Cy3_S_min_B_HIST(1:3) = nan; 
  
    %Cy5 
        Cy5_S_min_B = reshape(AT.',[],1); 
        Cy5_S_min_B = double(Cy5_S_min_B); 
        Cy5_S_min_B_HIST = hist(Cy5_S_min_B, 255); 
        %Remove the values from 1 to 3 intensity  
        Cy5_S_min_B_HIST(1:3) = nan; 
                      
% ISOTYPE control sub-threshold pixel removal 
  
i_thresholdT; 
  
first_sum = reshape(AT.',[],1); 
first_sum = sum(first_sum) 
  
col = 1; 
    while col <  Ncol 
       row = 1; 
       while row < Nrow 
  
    % Change every value that is below ISOTYPE CONTROL threshold to zero 
  
    % Cy3  
        % Remove Isotype Control Image Threshold 
            if A(row, col) < i_threshold 
                A(row, col) = 0; 
            end 
  
    % Cy5    
       % Remove Isotype Control Image Threshold 
            if AT(row, col) < i_thresholdT 
                AT(row, col) = 0; 
            end  
  
       row = row +1; 
      end 
       col = col +1; 
    end 
     
second_sum = reshape(AT.',[],1); 
second_sum = sum(second_sum) 
  
   
% Set the Sample - Isotype and Background subtrated matix to report as an 
image 
  
    %Cy3 
        Cy3_S_min_BI_grey = mat2gray(A); 
    %Cy5 
        Cy5_S_min_BI_grey = mat2gray(AT); 
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% Calculate the Isotype and Background subtracted images 
         
    %Cy3 
        Cy3_S_min_BI = reshape(A.',[],1); 
        Cy3_S_min_BI = double(Cy3_S_min_BI); 
        Cy3_S_min_BI_HIST = hist(Cy3_S_min_BI, 255); 
        %Remove the values from 1 to 3 intensity  
        Cy3_S_min_BI_HIST(1:3) = nan; 
  
    %Cy5 
        Cy5_S_min_BI = reshape(AT.',[],1); 
        Cy5_S_min_BI = double(Cy5_S_min_BI); 
        Cy5_S_min_BI_HIST = hist(Cy5_S_min_BI, 255); 
        %Remove the values from 1 to 3 intensity  
        Cy5_S_min_BI_HIST(1:3) = nan; 
   
% Report the values for the background and isotype control subtracted 
% images 
  
    B_n = sum(A); 
    C_n = sum(B_n); 
    Cy3_Cumulative_After = C_n; 
    AV_after = C_n /(Ncol*Nrow); 
    Cy3_Average_After = AV_after      
  
  
    B_n = sum(AT); 
    C_n = sum(B_n); 
    Cy5_Cumulative_After = C_n; 
    AV_after = C_n /(Ncol*Nrow); 
    Cy5_Average_After = AV_after    
     
  
 % Set grayscale images 
  
     %Cy3 
        Cy3_S = mat2gray(Aimage); 
        Cy3_I = mat2gray(iA); 
        Cy3_B = mat2gray(bA); 
      
     %Cy 5  
        Cy5_S = mat2gray(ATimage); 
        Cy5_I = mat2gray(iAT); 
        Cy5_B = mat2gray(bAT);        
      
% DISPLAY IMAGES 
  
    % First of Two Cy5 Histogram Images 
  
    figure 
     
    ax(1) = subplot(151); 
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    bar(Cy5_Sample_Histogram_Vector, 1, 'facecolor','green', 'EdgeColor', 
'none') 
    axis([0 51 0 150000]) 
    title 'Sample' 
  
    ax(2) = subplot(152); 
    mydata=Cy5_Background_Histogram_Vector_new; 
    bar_h=bar(mydata, 1); 
    bar_child=get(bar_h,'Children'); 
    set(bar_child,'CData',mydata); 
    mycolor=[1 0 0;0 0 0;0 1 0]; 
    for iCount=1:length(mydata) 
        if (iCount < Cy5_Background_Threshold_bin) 
                index(iCount)=1; 
            elseif (iCount == Cy5_Background_Threshold_bin) 
                index(iCount)=2; 
            elseif (iCount > Cy5_Background_Threshold_bin) 
                index(iCount)=3; 
        end 
    end 
    set(bar_child, 'CData',index); 
    colormap(mycolor); 
    set(bar_child, 'EdgeColor', 'none') 
    axis([0 51 0 150000]) 
    title 'Background' 
     
    ax(3) = subplot(153); 
    mydata=Cy5_S_minus_B; 
    bar_h=bar(mydata, 1); 
    bar_child=get(bar_h,'Children'); 
    set(bar_child,'CData',mydata); 
    mycolor=[1 0 0;0 0 0;0 1 0]; 
    for iCount=1:length(mydata) 
        if (iCount < Cy5_Background_Threshold_bin) 
                index(iCount)=1; 
            elseif (iCount == Cy5_Background_Threshold_bin) 
                index(iCount)=2; 
            elseif (iCount > Cy5_Background_Threshold_bin) 
                index(iCount)=3; 
        end 
    end 
    set(bar_child, 'CData',index); 
    colormap(mycolor); 
    set(bar_child, 'EdgeColor', 'none') 
    axis([0 51 0 150000]) 
    title 'Sample - Background' 
     
    % Second of Two Cy5 Histogram Images 
     
figure 
     
    ax(4) = subplot(154); 
    mydata=Cy5_Isotype_Histogram_Vector_new; 
    bar_h=bar(mydata, 1); 
    bar_child=get(bar_h,'Children'); 
    set(bar_child,'CData',mydata); 
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    mycolor=[1 0 0;0 0 0;0 1 0]; 
    for iCount=1:length(mydata) 
        if (iCount < Cy5_Isotype_Threshold_bin) 
                index(iCount)=1; 
            elseif (iCount == Cy5_Isotype_Threshold_bin) 
                index(iCount)=2; 
            elseif (iCount > Cy5_Isotype_Threshold_bin) 
                index(iCount)=3; 
        end 
    end 
    set(bar_child, 'CData',index); 
    colormap(mycolor); 
    set(bar_child, 'EdgeColor', 'none') 
    axis([0 51 0 150000]) 
    title 'Isotype' 
     
     
    ax(4) = subplot(155); 
    mydata = Cy5_S_minus_I; 
    bar_h=bar(mydata, 1); 
    bar_child=get(bar_h,'Children'); 
    set(bar_child,'CData',mydata); 
    mycolor=[1 0 0;0 0 0;0 1 0]; 
    for iCount=1:length(mydata) 
        if (iCount < Cy5_Isotype_Threshold_bin) 
                index(iCount)=1; 
            elseif (iCount == Cy5_Isotype_Threshold_bin) 
                index(iCount)=2; 
            elseif (iCount > Cy5_Isotype_Threshold_bin) 
                index(iCount)=3; 
        end 
    end 
    set(bar_child, 'CData',index); 
    colormap(mycolor); 
    set(bar_child, 'EdgeColor', 'none') 
    axis([0 51 0 150000]) 
    title 'Final Image' 
   
  
    %%%       Background subration images  
         
         
        figure 
  
        ax(1) = subplot(351); 
        imshow(Cy5_S) 
        colormap(jet(256)) 
        title('Cy5_S') 
         
        ax(2) = subplot(352); 
        imshow(Cy5_B) 
        colormap(jet(256)) 
        title('Cy5_B') 
         
        ax(3) = subplot(353); 
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        imshow(Cy5_S_min_B_grey) 
        colormap(jet(256)) 
        title('Cy5_S_-_B')        
         
        ax(4) = subplot(354); 
        imshow(Cy5_I) 
        colormap(jet(256)) 
        title('Cy5_I')  
         
        ax(5) = subplot(355); 
        imshow(Cy5_S_min_BI_grey) 
        colormap(jet(256)) 
        title('Cy5_S_-_B_-_I')  
          
        ax(6) = subplot(356); 
        imshow(Cy3_S) 
        colormap(jet(256)) 
        title('Cy3_S') 
         
        ax(7) = subplot(357); 
        imshow(Cy3_B) 
        colormap(jet(256)) 
        title('Cy3_B') 
         
        ax(8) = subplot(358); 
        imshow(Cy3_S_min_B_grey) 
        colormap(jet(256)) 
        title('Cy3_S_-_I')        
         
        ax(9) = subplot(359); 
        imshow(Cy3_I) 
        colormap(jet(256)) 
        title('Cy3_I')  
         
        ax(10) = subplot(3,5,10); 
        imshow(Cy3_S_min_BI_grey) 
        colormap(jet(256)) 
        title('Cy3_S_-_B_-_I')  
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6.1 IMAGE ANALYSIS SOFTWARE CODE – POPULATION SPECIFIC QUANTIFICATION 
 
The below image analysis Matlab 7.10.0 code was used to perform isotype control and background signal 
subtraction, while calculating representative histograms in specific cell populations. 
 
clear  
threshold = 0; 
% Image input - Cy3 & Cy5 VAIRABLE ARE ESPECIALLY FOR Cy3 AND Cy5 
% RESPECTIVELY (FOR PROPER COLOCALIZATION COEFFICIENT READOUT) 
  
%Import Images 
  
  
     % Sample Images  
    Cy3 = imread('Sample_Image_Cy3.tif'); %import picture - green channel = 
Cy3(:,:,2)% 
    Cy5 = imread('Sample_Image_Cy5.tif'); %import picture - red channel = 
Cy5(:,:,1)% 
  
    % Isotype Images (image from the antibody isotype control) 
    iCy3 = imread('Isotype_Image_Cy3.tif'); %import isotype control picture - 
green channel = Cy3(:,:,2)% 
    iCy5 = imread('Isotype_Image_Cy5.tif'); %import isotype control picture - 
red channel = Cy5(:,:,1)% 
     
    % Background Images (image from different plane - average is 200 microns 
under the sample, in the glass slide) 
    bCy3 = imread('Background_Image_Cy3.tif'); %import background picture - 
green channel = Cy3(:,:,2)% 
    bCy5 = imread('Background_Image_Cy5.tif'); %import background picture - 
red channel = Cy5(:,:,1)% 
  
  
%Background Thresholds   
     
    % Thresholds for the isotype control images 
    i_backlimit = .95;  % background Cy3 percent limit 
    i_backlimitT = .05; % background Cy5 percent limit (percentage of the 
pixels from the background image should be removed from the sample image) 
     
    % Thresholds for the background image                 
    backlimit = .95;  % background Cy3 percent limit 
    backlimitT = .05; % background Cy5 percent limit (percentage of the 
pixels from the background image should be removed from the sample image) 
  
% Create blank Scatter plot Matrix (255x255, all zeros) 
  
SP = zeros(256,256); 
NSP = zeros(256,256); 
  
% Green Channel (standard is Cy3) 
  
    % Sample Image 
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    X = size(Cy3);  
    A = Cy3; 
    A(:,:,1) = []; 
    A(:,:,2) = []; 
    Max3 = double(max(max(A))); % Maximum Cy3 value for the normalized 
scattergram 
  
    % Aimage for the unadjusted image output in the final figure 
    Aimage = A; 
     
    % Background Image 
    bX = size(bCy3);  
    bA = bCy3; 
    bA(:,:,1) = []; 
    bA(:,:,2) = []; 
  
    % Isotype Image 
    iX = size(iCy3);  
    iA = iCy3; 
    iA(:,:,1) = []; 
    iA(:,:,2) = []; 
     
    % Define variables for the first channel 
    Ncol = X(2); 
    col = 1; 
    Nrow = X(1); 
    row = 1; 
     
    % Calculate average pixel for the FIRST Channel 
     
    B = sum(A); 
    C = sum(B); 
    Cy3_Cumulative_Before = C 
    AV_before = C /(Ncol*Nrow); 
    Cy3_Average_Before = AV_before      
  
% Red Channel (standard is Cy5) 
  
    %Sample Image 
    XT = size(Cy5);  
    AT = Cy5; 
    AT(:,:,2) = []; 
    AT(:,:,2) = []; 
    Max5 = double(max(max(AT))); % Maximum Cy5 value for the normalized 
scattergram 
  
    % ATimage for the unadjusted image output in the final figure 
    ATimage = AT; 
   
    % Background Image 
    bXT = size(bCy5);  
    bAT = bCy5; 
    bAT(:,:,2) = []; 
    bAT(:,:,2) = []; 
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    % Isotype Image 
    iXT = size(iCy5);  
    iAT = iCy5; 
    iAT(:,:,2) = []; 
    iAT(:,:,2) = []; 
  
    %  Define variables for the SECOND channel 
  
    NcolT = XT(2); 
    colT = 1; 
    NrowT = XT(1); 
    rowT = 1; 
      
     % Calculate the average for the SECOND Channel  
      
     BT = sum(AT); 
     CT = sum(BT); 
     Cy5_Cumulative_before = CT; 
     AV_beforeT = CT/(Ncol*Nrow); 
     Cy5_Average_Before= AV_beforeT;  
  
% Background calculation to identify threshold 
      
     % Cy3 calculation 
                                     
            % Background Image Subtraction 
                bA = double(bA); 
                n_vector = reshape(bA.',[],1); 
                n_vector_d = double(n_vector); 
                n_b_HIST = hist(n_vector_d, 255); 
                Sum_shar = sum(n_b_HIST);  % sum of all pixels 
                w = Sum_shar * backlimit; % number of pixels above backlimit  
                rest = Sum_shar - w; % number of pixels below the 5% 
threshold 
                i = 1; % background loop index and threshold value (after the 
loop is ran) 
                y = 0; % cumulation of pixels below threshold 
                while y < w; 
                    y = y + n_b_HIST(i); 
                    i=i+1; 
                end 
                 
                                
                threshold = i-1; 
                        
          threshold = 0; 
                 
            % Isotype Control Image Subraction             
                iA = double(iA); 
                n_vector = reshape(iA.',[],1); 
                n_vector_d = double(n_vector); 
                n_b_HIST = hist(n_vector_d, 255); 
                Sum_shar = sum(n_b_HIST);  % sum of all pixels 
                w = Sum_shar * backlimit; % number of pixels above backlimit  
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                rest = Sum_shar - w; % number of pixels below the 5% 
threshold 
                i = 1; % background loop index and threshold value (after the 
loop is ran) 
                y = 0; % cumulation of pixels below threshold 
                while y < w; 
                    y = y + n_b_HIST(i); 
                    i=i+1; 
                end 
                i_threshold = i-1; 
  
             i_threshold = 0;   
                 
     % Cy5 calculation 
             
            % Background Control Image Threshold Calculation                
  
                bAT = double(bAT); 
                nT_vector = reshape(bAT.',[],1); 
                nT_vector_d = double(nT_vector); 
                Sum_nT_vector_d = sum(nT_vector_d); % Sum_nT_vector_d = Sum 
of all pixel intensities 
                Sum_nT_vector_d_limit = Sum_nT_vector_d * backlimitT; % 
Sum_nT_vector_d_limit = value of pixels below threshold  
                nT_b_HIST = hist(nT_vector_d, 255); 
                Sum_nT_b_HIST = sum(nT_b_HIST); 
                HIST_Limit = Sum_nT_b_HIST * backlimitT; 
                iT = 1; % background loop index (and threshold value - after 
the loop is ran) 
                yT = 0; % accumulation of pixels below backlimit 
                % find the intensity when the threshold exists 
                while yT < HIST_Limit; 
                    % yT = current value leading up to Sum_sharT (Sum_sharT = 
the sum of pixels below the threshold), frequency = (nT_b_HIST(iT)),  
intensity = (iT)  
                    yT = yT + (nT_b_HIST(iT)); 
                    iT=iT+1; 
                end 
                                 
                thresholdT = iT-1; 
                 
            thresholdT = 0; 
                 
                %Cy5_Background_Threshold = the intensity below which 
                %sample pixel will be excluded. 
                 
                Cy5_Background_Threshold = thresholdT;  
                Cy5_Background_Threshold_bin = round(thresholdT/5);  
                               
  
            % Isotype Control Image Threshold Calculation        
                 
                iAT = double(iAT); 
                nT_vector = reshape(iAT.',[],1); 
                nT_vector_d = double(nT_vector); 
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                Sum_nT_vector_d = sum(nT_vector_d); % Sum_nT_vector_d = Sum 
of all pixel intensities 
                Sum_nT_vector_d_limit = Sum_nT_vector_d * i_backlimitT; % 
Sum_nT_vector_d_limit = value of pixels below threshold  
                nT_b_HIST = hist(nT_vector_d, 255); 
                Sum_nT_b_HIST = sum(nT_b_HIST); 
                HIST_Limit = Sum_nT_b_HIST * i_backlimitT; 
                iT = 1; % background loop index (and threshold value - after 
the loop is ran) 
                yT = 0; % accumulation of pixels below backlimit 
                % find the intensity when the threshold exists 
                while yT < HIST_Limit; 
                    % yT = current value leading up to Sum_sharT (Sum_sharT = 
the sum of pixels below the threshold), frequency = (nT_b_HIST(iT)),  
intensity = (iT)  
                    HIST_Limit; 
                    yT = yT + (nT_b_HIST(iT)); 
                    iT=iT+1; 
                end 
                 
                 
                i_thresholdT = iT-1; 
                 
             i_thresholdT = 0;  
                 
                 
                %Cy5_Isotype_Threshold = the intensity below which 
                %sample pixel will be excluded. 
                 
                Cy5_Isotype_Threshold = i_thresholdT; 
                Cy5_Isotype_Threshold_bin = round(i_thresholdT/5); 
  
  
                % define arbitrary variable values for the while loop 
  
                p = 0; 
                q = 0; 
                tdif = 0; 
                dif = 0; 
                tavg = 0; 
                tavgt = 0;  
                tclc = 0; 
                gel = 0; 
                counted = 0; 
  
  
                    % Validates that images are of the same dimensions  
  
                    if (Ncol ~= NcolT); 
                        error('images of different sizes') 
                    end 
  
                    if (Nrow ~= NrowT); 
                        error('images of different sizes') 
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                    end 
                     
                     
% Generate a histogram of intensities from the Cy5 image 
  
%Sample Image 
    Cy5_vector = reshape(AT.',[],1); 
    Cy5_vector_d = double(Cy5_vector); 
    Cy5_HIST = hist(Cy5_vector_d, 100); 
  
%Background Image  
    Cy5_b_vector = reshape(bAT.',[],1); 
    Cy5_b_vector_d = double(Cy5_b_vector); 
    Cy5_b_HIST = hist(Cy5_b_vector_d, 100); 
  
%Isotype control Image  
    Cy5_i_vector = reshape(iAT.',[],1); 
    Cy5_i_vector_d = double(Cy5_i_vector); 
    Cy5_i_HIST = hist(Cy5_i_vector_d, 100); 
  
% Generate custom histograms of intensities from the Cy5 image for plotting 
with the bar function     
  
% Sample Image Histogram Calculations 
    % Reshape the image into a vector        
        Cy5_Image_vector = reshape(AT.',[],1); 
        Cy5_Image_vector = double(Cy5_Image_vector); 
    % Set the histogram vector to 255 zeros 
        Cy5_Sample_Histogram_Vector = zeros([1 51]); 
    % Bin the pixel intensity values into the histogram vector     
        i=1; 
        % Loop through the image vector 
        while i <= length(Cy5_Image_vector) 
            t=1; 
            y=0; 
            % Place the pixel values into the histogram vector 
            while y < 1 
                bins = 5*t; 
                if Cy5_Image_vector(i) <= bins 
                    Cy5_Sample_Histogram_Vector(t) = 
Cy5_Sample_Histogram_Vector(t) + 1; 
                    y = 2; 
                end 
            t=t+1; 
            end 
                         
            i=i+1; 
        end 
         
        Cy5_Sample_Histogram_Vector_new = Cy5_Sample_Histogram_Vector; 
         
% Background Image Histogram Calculations 
    % Reshape the image into a vector        
        Cy5_Background_vector = reshape(bAT.',[],1); 
        Cy5_Background_vector = double(Cy5_Background_vector); 
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    % Set the histogram vector to 255 zeros 
        Cy5_Background_Histogram_Vector = zeros([1 51]); 
    % Bin the pixel intensity values into the histogram vector     
        i=1; 
        % Loop through the Background vector 
        while i <= length(Cy5_Background_vector) 
            t=1; 
            y=0; 
            % Place the pixel values into the histogram vector 
            while y < 1 
                bins = 5*t; 
                if Cy5_Background_vector(i) <= bins 
                    Cy5_Background_Histogram_Vector(t) = 
Cy5_Background_Histogram_Vector(t) + 1; 
                    y = 2; 
                end 
            t=t+1; 
            end 
                         
            i=i+1; 
        end 
         
% Bin the background threshold into the original         
        Cy5_Background_Threshold_bin = round(Cy5_Background_Threshold / 5) ; 
        Cy5_Background_Histogram_Vector_new = 
Cy5_Background_Histogram_Vector; 
  
% In Cy5_S_minus_B, set all values below the Cy5_Background_Threshold equal 
to zero.  
        Cy5_S_minus_B = Cy5_Sample_Histogram_Vector; 
        %Loop through Cy5_S_minus_B_before, setting everything below 
Cy5_Background_Threshold equal to zero.   
            i=1; 
            Cy5_Background_Threshold_Bin = ((Cy5_Background_Threshold/5)-1); 
            while i < Cy5_Background_Threshold_Bin 
                    Cy5_S_minus_B(i) = 0; 
                  i=i+1; 
            end 
          
             
% Isotype Image Histogram Calculations 
    % Reshape the image into a vector        
        Cy5_Isotype_vector = reshape(iAT.',[],1); 
        Cy5_Isotype_vector = double(Cy5_Isotype_vector); 
    % Set the histogram vector to 255 zeros 
        Cy5_Isotype_Histogram_Vector = zeros([1 51]); 
    % Bin the pixel intensity values into the histogram vector     
        i=1; 
        % Loop through the Isotype vector 
        while i <= length(Cy5_Isotype_vector) 
            t=1;     
            y=0; 
            % Place the pixel values into the histogram vector 
            while y < 1 
                bins = 5*t; 
                if Cy5_Isotype_vector(i) <= bins 
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                    Cy5_Isotype_Histogram_Vector(t) = 
Cy5_Isotype_Histogram_Vector(t) + 1; 
                    y = 2; 
                end 
            t=t+1; 
            end 
                         
            i=i+1; 
        end 
         
% Bin the Isotype threshold into the original         
        Cy5_Isotype_Threshold_bin = round(Cy5_Isotype_Threshold / 5) ; 
        Cy5_Isotype_Histogram_Vector_new = Cy5_Isotype_Histogram_Vector; 
         
         
         
       % Cy5_Isotype_Threshold_bin = Cy5_Isotype_Threshold_bin + 3; 
  
  
% In Cy5_S_minus_I, set all values below the Cy5_Isotype_Threshold equal to 
zero.  
        Cy5_S_minus_I = Cy5_S_minus_B; 
        %Loop through Cy5_S_minus_I_before, setting everything below 
Cy5_Isotype_Threshold equal to zero.   
            i=1; 
            %Cy5_Isotype_Threshold_Bin = Cy5_Isotype_Threshold_Bin-1; 
            while i < Cy5_Isotype_Threshold_bin 
                    Cy5_S_minus_I(i) = 0; 
                    i=i+1; 
            end         
         
  
             
% BACKGROUND control sub-threshold pixel removal 
  
col = 1; 
  
    while col <  Ncol 
       row = 1; 
       while row < Nrow 
  
    % Change every value that is below BACKGROUND threshold to zero 
  
    % Cy3  
        % Remove BACKGROUND AND ISOTYPE Control Image Threshold 
            if A(row, col) < threshold 
                A(row, col) = 0; 
            end 
  
    % Cy5    
       % Remove BACKGROUND AND ISOTYPE Control Image Threshold 
            if AT(row, col) < thresholdT 
                AT(row, col) = 0; 
            end  
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       row = row +1; 
      end 
       col = col +1; 
    end             
             
% Set the Sample - Background subtrated matix to report as an image 
  
    %Cy3 
        Cy3_S_min_B_grey = mat2gray(A); 
    %Cy5 
        Cy5_S_min_B_grey = mat2gray(AT); 
  
% Calculate the Background subtracted images 
         
    %Cy3 
        Cy3_S_min_B = reshape(A.',[],1); 
        Cy3_S_min_B = double(Cy3_S_min_B); 
        Cy3_S_min_B_HIST = hist(Cy3_S_min_B, 255); 
        %Remove the values from 1 to 3 intensity  
        Cy3_S_min_B_HIST(1:3) = nan; 
  
    %Cy5 
        Cy5_S_min_B = reshape(AT.',[],1); 
        Cy5_S_min_B = double(Cy5_S_min_B); 
        Cy5_S_min_B_HIST = hist(Cy5_S_min_B, 255); 
        %Remove the values from 1 to 3 intensity  
        Cy5_S_min_B_HIST(1:3) = nan; 
                      
% ISOTYPE control sub-threshold pixel removal 
  
  
  
i_thresholdT; 
  
first_sum = reshape(AT.',[],1); 
first_sum = sum(first_sum); 
  
  
  
  
col = 1; 
    while col <  Ncol 
       row = 1; 
       while row < Nrow 
  
    % Change every value that is below ISOTYPE CONTROL threshold to zero 
  
    % Cy3  
        % Remove Isotype Control Image Threshold 
            if A(row, col) < i_threshold 
                A(row, col) = 0; 
            end 
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    % Cy5    
       % Remove Isotype Control Image Threshold 
            if AT(row, col) < i_thresholdT 
                AT(row, col) = 0; 
            end  
  
       row = row +1; 
      end 
       col = col +1; 
    end 
     
second_sum = reshape(AT.',[],1); 
second_sum = sum(second_sum) 
  
   
% Set the Sample - Isotype and Background subtrated matix to report as an 
image 
  
    %Cy3 
        Cy3_S_min_BI_grey = mat2gray(A); 
    %Cy5    
        Cy5_S_min_BI_grey = mat2gray(AT); 
  
% Report the values for the background and isotype control subtracted 
% images 
  
    B_n = sum(A); 
    C_n = sum(B_n); 
    Cy3_Cumulative_After = C_n; 
    AV_after = C_n /(Ncol*Nrow); 
    Cy3_Average_After = AV_after      
    AV = Cy3_Average_After; 
  
    B_n = sum(AT); 
    C_n = sum(B_n); 
    Cy5_Cumulative_After = C_n; 
    AV_after = C_n /(Ncol*Nrow); 
    Cy5_Average_After = AV_after    
    AVT = Cy5_Average_After;   
         
% redefine arbitrary variable values for the while loop 
  
    p = 0; 
    q = 0; 
    tdif = 0; 
    dif = 0; 
    tavg = 0; 
    tavgt = 0;  
    tclc = 0; 
    col = 1; 
  
% Iterations to quantify individual pixels 
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while col <  Ncol 
   row = 1; 
   while row < Nrow 
            
   % P / PT are the indexed pixel values     
   P = double(A(row,col)); % Cy3 - green channel 
   PT = double(AT(row,col)); % Cy5 - red channel 
    
   % Generate Scattergram 
   SP((P+1),(PT+1)) = SP((P+1),(PT+1))+50;   
  
   % SUM 1 
   dif = (P - AV) * (PT - AVT); 
   tdif = dif + tdif;  
    
   % SUM 2 
   avg = (P - AV)^2; 
   tavg = avg + tavg; 
    
   % SUM 3 
   avgt = (PT - AVT)^2; 
   tavgt = tavgt + avgt; 
    
    % Cy 3 channel    
    
    % (t is a 'switch' for accumulating colocalization coefficient values, 
    % if it is changes to '1', then the Cy3 has a positive pixel, and Cy5 
    % will be checked for a positive pixel as well 
     
    t = 0; 
    if A(row,col) > i_threshold 
        p = p+1; 
        t = 1; 
    end 
     
    % Cy 5 channel 
    if AT(row,col) > i_thresholdT 
        q = q+1; 
        if t > 0 
            clc = 1; 
            tclc = clc + tclc; 
        end 
    end 
  
    row = row +1; 
   end 
   col = col +1; 
end 
  
col = 1; 
Ncol = 256; 
Nrow = 256; 
  
while col <  Ncol 
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   row = 1; 
   while row < Nrow 
             
       if row == 1 
            SP(row, col) = 0; 
       end 
       if col == 1 
            SP(row, col) = 0; 
       end 
   row = row +1; 
   end 
   col = col +1; 
end  
  
% Pearson's Correlation Coefficient 
pearson = tdif / sqrt (tavg * tavgt) 
  
% Colocalization Coefficients 
Cy3clc = tclc / p;   % Percentage of Cy3 pixels that colocalize to Cy5 
Cy5clc = tclc / q   % Percentage of Cy5 pixels that colocalize to Cy3  
  
% Signal Quantification 
Cy3pix = p; 
Cy5pix = q; 
Cy5normCy3 = q/p; 
  
% Image Scatter Gram 
SPU = double(SP); 
SPUgray = mat2gray(SPU); 
  
% Amplify all values 
col = 1; 
Ncol = 256; 
Nrow = 256; 
  
while col <  Ncol 
   row = 1; 
   while row < Nrow 
       if SPUgray(row, col) > 0    
            SPUgray(row, col) = 255; 
       end 
       row = row +1; 
   end 
   col = col +1; 
end  
  
C_Scatter = zeros(256,256,3); 
  
% Put values of SPU scattergram into C_Scatter matrix 
col = 1; 
Ncol = 256; 
Nrow = 256; 
  
while col <  Ncol 
   row = 1; 
APPENDIX                          116 
   while row < Nrow 
       if SPUgray(row, col) > 0    
            C_Scatter(row,col,2) = SPUgray(row, col); 
       end 
       row = row +1; 
   end 
   col = col +1; 
end 
  
%Make a Scattergram from the double isotype control matrix 
col = 1; 
Ncol = 256; 
Nrow = 256; 
  
bSP = zeros(256,256);  
  
while col <  Ncol 
   row = 1; 
   while row < Nrow 
            
       % bP / bPT are the indexed pixel values     
       bP = double(bA(row,col)); % Cy3 - green channel 
       bPT = double(bAT(row,col)); % Cy5 - red channel 
  
       % Generate Scattergram 
       bSP((bP+1),(bPT+1)) = bSP((bP+1),(bPT+1))+50;   
  
        row = row +1; 
   end 
   col = col +1; 
end 
  
%Put values of iSP into C_Scatter 
col = 1; 
Ncol = 256; 
Nrow = 256; 
  
  
while col <  Ncol 
   row = 1; 
   while row < Nrow 
        if  bSP(row, col) > 0 
            C_Scatter(row,col,2) = 0; 
            C_Scatter(row,col,3) = 255; 
        end 
        row = row +1; 
   end 
   col = col +1; 
end 
  
  
  
  
%Make a Scattergram from the isotype matrix 
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col = 1; 
Ncol = 256; 
Nrow = 256; 
  
iSP = zeros(256,256);  
  
while col <  Ncol 
   row = 1; 
   while row < Nrow 
            
       % iP / iPT are the indexed pixel values     
       iP = double(iA(row,col)); % Cy3 - green channel 
       iPT = double(iAT(row,col)); % Cy5 - red channel 
  
       % Generate Scattergram 
       iSP((iP+1),(iPT+1)) = iSP((iP+1),(iPT+1))+50;   
  
        row = row +1; 
   end 
   col = col +1; 
end 
  
%Put values of iSP into C_Scatter 
col = 1; 
Ncol = 256; 
Nrow = 256; 
  
  
while col <  Ncol 
   row = 1; 
   while row < Nrow 
        if  iSP(row, col) > 0 
            C_Scatter(row,col,2) = 0; 
            C_Scatter(row,col,1) = 255; 
            C_Scatter(row,col,3) = 0; 
        end 
        row = row +1; 
   end 
   col = col +1; 
end 
  
  
% Plot both Normalized and Raw intensity scattergrams 
   
    figure 
    imshow(C_Scatter) 
  
% Calculate the Isotype and Background subtracted images 
         
    %Cy3 
        Cy3_S_min_BI = reshape(A.',[],1); 
        Cy3_S_min_BI = double(Cy3_S_min_BI); 
        Cy3_S_min_BI_HIST = hist(Cy3_S_min_BI, 255); 
        %Remove the values from 1 to 3 intensity  
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        Cy3_S_min_BI_HIST(1:3) = nan; 
  
    %Cy5 
        Cy5_S_min_BI = reshape(AT.',[],1); 
        Cy5_S_min_BI = double(Cy5_S_min_BI); 
        Cy5_S_min_BI_HIST = hist(Cy5_S_min_BI, 255); 
        %Remove the values from 1 to 3 intensity  
        Cy5_S_min_BI_HIST(1:3) = nan; 
   
  
  
 % Set grayscale images 
  
     %Cy3 
        Cy3_S = mat2gray(Aimage); 
        Cy3_I = mat2gray(iA); 
        Cy3_B = mat2gray(bA); 
      
     %Cy 5  
        Cy5_S = mat2gray(ATimage); 
        Cy5_I = mat2gray(iAT); 
        Cy5_B = mat2gray(bAT);        
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